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CHaPTEr 1
General introduction and 




Coeliac disease (CD) is an immune-mediated systemic disorder elicited by gluten in 
genetically susceptible individuals. It is characterized by anti-tissue transglutaminase 
type 2 antibodies (TG2A) and enteropathy1. In individuals carrying the human leucocyte 
antigen (HLA)-DQ2 and/or DQ8 haplotype, the ingestion of gluten (a group of proteins 
present in cereals such as wheat, barley and rye) can cause a T cell-initiated inflamma-
tory response, damaging the small bowel mucosa2. In the general population, the preva-
lence of CD amongst adults as well as children is nearly 1-3%3,4. The disease is even 
more frequent in individuals with other autoimmune diseases such as type 1 diabetes 
mellitus (T1DM), auto-immune thyroiditis or in specific syndromes such as Down and 
Turner syndrome (10-15%)5. In first degree relatives of coeliac patients, the prevalence 
is 5-15%6,7.
Clinical presentation
The disease has a variable clinical presentation, ranging from malabsorption with diar-
rhoea, abdominal distension and weight loss, to nonspecific signs and symptoms such as 
fatigue, osteoporosis or iron deficiency anaemia. This diversity of signs and symptoms, 
in combination with the fact that some individuals do not even have complaints, leads 
to the so-called ice-berg phenomenon, with most cases of CD being unrecognised and 
thus untreated8,9. These different types of presentation have led to a classification into 
different subcategories: classical, silent and potential CD (Table 1)10,11. A high index of 
suspicion is warranted by doctors but also by the general population, in order to diminish 
the diagnostic delay most patients encounter12.
Table 1 Subcategories of coeliac disease
Coeliac disease Symptoms CD-specific antibodies Small bowel histological abnormalities
Classical + + +
Silent - + +
Potential +/- + -





When CD is suspected, non-invasive tests can be used, measuring CD-specific antibodies 
(IgA class tissue transglutaminase antibodies, TG2A, anti-endomysium antibodies (EMA) 
or antibodies against deaminated gliadin peptides (DGPA))13,14. Interpretation of these 
autoantibodies starts with total IgA assessment, since coeliac disease is associated with 
selective IgA deficiency15,16. In IgA deficiency, IgG dependent antibodies can be tested, 
with IgG EMA, TG2A and DGPA being available. Sensitivity and specificity of both IgA 
EMA and TG2A and DGPA are high and in concordance with small bowel histological ab-
normalities: 98% and 90% in severe duodenal lesions, and 97% and 98% in less severe 
intestinal damage respectively17.
HLA-genotyping
Furthermore, genotyping for HLA-DQ2 and HLA-DQ8 adds value to the diagnostic scheme, 
since CD has a strong genetic component. Approximately 90% of coeliac  patients carry 
the HLA-DQ2 haplotype, about 5% the HLA-DQ8 molecule18–21 and the rest usually one 
half of the HLA-DQ2 heterodimer (DQA1-0505). The different heterodimers formed by 
HLA-DQA1* and HLA-DQB1* genes on the surface of antigen presenting cells contribute 
to the development of CD by the capacity to present gluten to T-cells which initiates the 
immune response. The HLA-DQ2 and DQ8 haplotypes are present in more than 25% of 
the general population20, but only 1% actually develops CD4. This indicates that HLA-DQ2 
and/or HLA-DQ8 haplotypes are necessary but not sufficient for disease development. In 
recent years, non-HLA genes have been reported to be associated with CD but with only 
a modest effect22,23.
Intestinal histology
Finally, CD is characterized by small bowel mucosa alterations, referred to as gluten-
sensitive enteropathy, which is categorized according to the Marsh classification14. 
Marsh classification type 3 or type 2 together with specific coeliac serology support 
the diagnosis of CD. These small bowel biopsies are obtained by means of esophago-
gastro-duodenal endoscopy, an invasive method, especially in children needing gen-
eral anaesthesia or deep sedation for the procedure. Until recent years, the histological 
 assessment of duodenal biopsies has been the gold standard for the diagnosis of CD. 
However, patchiness of villous atrophy24,25 but also difficulties with regard to proper in-
terpretation, cutting and orientation of duodenal biopsies in order to come to a precise 
Marsh-classification can lead to false negative but also false positive biopsy results. 
Therefore, the histological interpretation needs to be done by an experienced patholo-
gist with the patient’s clinical complaints, serology and HLA-type in mind. In 2012, the 
European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) 
proposed an exception with regard to performing duodenal biopsies for a well-defined 
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group of children, having high titers of TG2A (>10 times upper limit of normal), positive 
EMA and positive HLA-DQ2/DQ81. This strategy has been shown to be valid in 2017 by 
a multicentre European prospective study26. However, it still raises a lot of debate in 
adults suspected of CD and it is challenged for example by pediatric gastroenterologists 
from the United States of America27.
Treatment
CD can be successfully treated with a gluten free diet (GFD) which restores small bowel 
histology and improves symptoms. However, this diet may be difficult to follow and may 
lead to social constraints. It is known that dietary adherence differs among individuals, 
with noncompliance varying from 25-50% among children and adolescents28–30. Noncom-
pliance can be intentional, but accidental gluten ingestion also happens because of con-
tamination of non-toxic cereals such as oats or corn due to co-culture or spilling during 
transport. Contamination can also take place during food-processing either in factories or 
at home. The capacity of gluten to improve the properties of food and non-food such as 
pencils and glue, increases the risk of contamination even more. Besides the impact of a 
GDF on a patient’s daily and social life, the GFD can also lead to nutritional deficiencies 
since gluten-containing cereals like wheat, barley and rye are important sources of di-
etary iron, calcium, folate and vitamin B1228,31,32,33. Gluten-free grains such as buckwheat 
or quinoa are naturally rich in group B vitamins34 but commercially available gluten-free 
products do not contain the same amount of iron, vitamin B12 and folate as the wheat 
flour products that they aim to replace35,36. Therefore, testing for anaemia, iron status 
and calcium, folic acid, vitamin B12 and vitamin D is common practice in patients with 
CD treated with a GFD. At the time of initiating this thesis, studies investigating the actual 
presence of nutritional deficiencies in children on a GFD, however, were lacking.
Follow-up
Despite the knowledge that non-compliance often occurs, a gold standard to assess 
compliance is lacking37. An extensive dietary evaluation by a trained dietitian is con-
sidered the best method38, but not very practical due to its time-consuming nature. 
Repeat duodenal biopsies to monitor mucosal recovery is usually not a practical option, 
especially in children wherein endoscopy to obtain biopsies is done under anaesthesia 
or deep sedation. Serologic testing is not sensitive enough to detect infrequent gluten 
exposure39–41, although it is usually performed in CD patients who are on a GFD. When 
this thesis commenced, several short dietary questionnaires had been developed in 
order to save time and to address compliance in a standard manner. However, they were 




The Dutch and European CD guidelines recommend testing for CD in asymptomatic 
individuals with increased risk for CD: other autoimmune diseases such as T1DM, auto-
immune thyroid and liver disease, Down, Turner and Williams syndrome, selective IgA 
deficiency and first degree relatives (FDRs) of coeliac patients1,42. Because of the high 
negative predictive value of HLA-typing for CD, unnecessary investigations in HLA-DQ2 
and DQ8 negative individuals can be avoided. Therefore, HLA-typing can be offered to 
these individuals, albeit that due to its high costs in combination with a shared genetic 
background already predisposing to the same HLA-type, it is debated in certain risk 
groups, such as T1DM43,44. At the time of initiating this thesis, the impact of screening 
for CD on parents and perceived health of FDRs had not been studied, neither was the 
best suited screening frequency.
With regard to children with diabetes, several consensus based guidelines have different 
screening and treatment recommendations. Some suggest to screen all T1DM patients 
for CD1,45,46, but state that while it seems sensible to put also an asymptomatic child 
on a GFD to avoid the development of complications, limited data are available to sup-
port this. Conversely, other guidelines advise screening only in symptomatic T1DM pa-
tients and emphasize informing parents that the treatment of asymptomatic CD in T1D 
is controversial47,48. Despite high sensitivity and specificity, the interpretation of TG2A 
and EMA in children with T1DM has proven difficult. The 2012 ESPGHAN guideline rec-
ommends duodenal biopsies if TG2A titers are >3xULN in asymptomatic individuals1. 
However, elevated TG2A titers often show spontaneous normalization in children with 
T1DM49 and people at genetic risk for CD (like children with T1DM) have more often false-
positive TG2A results50. Altogether, it leaves clinicians without a concrete method of 
patient management and speak to the absence of available literature for development 
of an evidence-based approach.
Outline of this thesis
With much attention in CD related research on diagnostics, prevention and new thera-
peutic modalities, the focus of this thesis has been on two clinical aspects of pediatric 
CD: the monitoring methods used during follow-up (Part I) and the screening process of 
individuals at risk (Part II). The specific questions addressed in my thesis are presented 
in Table 2.
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Part I Follow-up
In Chapter 2, the results of a retrospective analysis of all complementary serologic 
investigations done at time of diagnose and during annual follow-up of children with CD 
are presented in order to describe the course of nutritional deficiencies after treatment. 
Chapter 3 investigates whether a short standardized dietary questionnaire correlates 
with the dietary interview performed by a dietician in children with CD and how both 
match with CD specific serology.
Part II Risk Groups
The impact of HLA-typing in healthy children from coeliac families on parents is dis-
cussed in Chapter 4, together with the parental knowledge on the genetic background 
of CD and whether they would repeat HLA-typing in future children. Chapter 5 also 
addresses coeliac families and describes the effect of sex, HLA-type and age of FDRs at 
time of CD diagnosis in the index coeliac patient in order to establish a better screening 
protocol for these high risk individuals. Chapter 6 challenges the current recommenda-
tion for asymptomatic diabetic children with TG2A titers >3x the upper limit of normal 
(ULN) to be biopsied by means of Receiver Operating Characteristic (ROC) analyses of 
TG2A levels and corresponding duodenal histology.
Table 2  Questions addressed in this thesis
1 Do nutritional deficiencies persist in coeliac children after start of a GFD?
2 Do short GFD questionnaires detect infrequent dietary transgressions in coeliac children?
3 What is the impact of HLA-screening in children at risk for coeliac development?
4 What is the best screening method in FDRs of newly diagnosed coeliac patients?
5 When should duodenal biopsies be performed in T1DM children with elevated TG2A serology, since serology is 
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ObjectIves To determine the frequency of nutritional deficiencies and thyroid dys-
function in children with coeliac disease (CD) at diagnosis and during follow-up after 
initiation of a gluten-free diet, since laboratory investigations of hemoglobin, ferritin, 
calcium, folate, vitamin B12, vitamin D and thyroid function are regularly ordered in CD 
children despite sufficient evidence for these.
MethOds Between 2009 and 2014, test results of hemoglobin, ferritin, folate, vitamin 
B12, calcium, vitamin D-25-OH, FT4 and TSH of CD children regularly seen at the Leiden 
University Medical Center were investigated. Laboratory reference ranges were used to 
define abnormal results. Pearson’s chi-square test for trend, unpaired t-test and one-
way ANOVA were used for statistical analysis.
results 182 children were evaluated, wherein 119 were new diagnoses. On average, 17% 
of results per year were missing due to incomplete blood investigations. Iron  deficiency 
(28%) and iron deficiency anemia (9%) were found upon CD diagnosis. Folate (14%), vita-
min B12 (1%) and vitamin D deficiencies (27%) were also seen. No hypocalcemia or thyroid 
dysfunction was found. At follow-up, iron deficiency, iron deficiency anemia, folate and 
vitamin D deficiency were respectively observed in 8%, 2%, 3% and 25% of patients. No 
vitamin B12 deficiency, hypocalcemia or thyroid disease was found.
cOnclusIOn Complementary blood investigations are relevant at time of CD diagno-
sis but have little diagnostic yield during follow-up visits once the patient is placed on a 
gluten-free diet. Thus, we recommend that these variables only be assessed on indica-




Coeliac disease (CD) is an immune-mediated systemic disorder elicited by gluten in 
genetically susceptible individuals. It is characterized by anti-tissue transglutaminase 
type 2 antibodies (TG2A) and enteropathy1. The disease can be successfully treated with 
a gluten-free diet (GFD)2. Small bowel mucosal damage in CD patients can lead to malab-
sorption and, subsequently, nutritional deficiencies causing osteoporosis, iron deficiency 
(ID) or iron deficiency anemia (IDA). Since gluten-containing cereals like wheat, barley 
and rye are important sources of dietary iron, calcium, folate and vitamin B12, the treat-
ment of CD with a GFD can also lead to nutritional deficiencies3-6. Gluten-free grains such 
as buckwheat or quinoa are naturally rich in group B vitamins7 but commercially available 
gluten-free products do not contain the same amount of iron, vitamin B12 and folate as 
the wheat flour products that they aim to replace8,9. A lack of variation in food choices, 
often seen in CD children10, may aggravate the problem11. It is common practice to check 
the CD patients’ ID/IDA indices (i.e. a complete blood count, including mean corpuscu-
lar volume, red cell distribution width, serum ferritin), calcium, folate and vitamin B12 
levels, both at diagnosis and at follow-up. However, there is limited information on the 
incidence of nutritional deficiencies in patients with treated CD. Some evidence based 
CD guidelines such as the one from the National Institutes of Health (NIH)12 and the 
Dutch Society for Gastroenterology13 recommend that all aforementioned blood tests 
continue to be performed in patients who already receive ongoing medical treatment for 
their CD. Other CD guidelines such as those by the European Society for Pediatric Gastro-
enterology Hepatology and Nutrition (ESPGHAN)1, the National Institute for Health and 
Care Excellence (NICE)14 or the North American Society for Pediatric Gastroenterology 
Hepatology and Nutrition (NASPGHAN)15 provide no guidance on the matter. In addition, 
several guidelines recommend testing for thyroid autoimmunity at various intervals but 
give no information on how frequently this should be done13,16.
Our study’s primary aims were to assess the frequency of nutritional deficiencies, 
specifically iron (and the iron deficiency anemia that may follow), calcium, folate and 
vitamin B12, and to determine the presence of thyroid dysfunction among CD children at 
the time of diagnosis and at follow-up while on a GFD. The secondary aim was to deter-
mine whether these investigations were necessary in the routine follow-up of children 
with treated CD.
Methods
We analyzed the blood testing results of all CD children who had medical checks be-
tween January 2009 and January 2015 at the Leiden University Medical Center (LUMC).
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Complementary investigations during follow-up
CD was diagnosed according to the ESPGHAN criteria1. After diagnosis, these children 
were then seen regularly according to (inter-)national guidelines. These visits included 
blood investigations1,13, particularly CD-specific antibodies, hemoglobin (determined by 
Sysmex XE-2100), ferritin, folate, vitamin B12 (all measured by ECLIA using Roche Modu-
lar E170), free thyroxin (FT4) and thyroid stimulating hormone (TSH) (both determined by 
colorimetric assay IFCC). Calcium levels (measured by Roche Modular P800) and vitamin 
D-25-OH (determined by ECLIA using Roche Modular E170) were only recorded begin-
ning in 2012 because our department had only started doing these routine investiga-
tions in CD patients after 2011. Laboratory reference ranges per blood parameter are 
shown in Table 1. IDA was defined as ID plus anemia17. Hypothyroidism was defined as 
an FT4 < 10 pmol/L and TSH > 4.8 mU/L while hyperthyroidism was defined following 
an FT4 > 24 pmol/L and TSH < 0.3 mU/L.
We registered the following patient data: sex, date of birth, age at CD diagnosis, coeliac 
antibodies, HLA-typing, Marsh histologic classifications of the diagnostic small bowel 
biopsies, and date of blood extraction. The time of CD diagnosis was defined as the date 
of diagnostic small bowel biopsies or, if there was no indication for a diagnostic biopsy, 
the date when high titers of endomysial antibodies (EMA) and TG2A in the serum were 
Table 1 Laboratory reference range used to define abnormal results.
Biochemical parameter Limit of abnormal value
Hemoglobin, age <7 years < 6.9 mmol/L (< 11.0 g/dL)
Hemoglobin, age 7-15 years < 6.5 mmol/L (< 10.4 g/dL)
Hemoglobin, age >15 years < 6 mmol/L (<9.6 g/dL)
Ferritin, age <5 years < 12 ug/L
Ferritin, age ≥5 years < 15 ug/L
Folate < 10 nmol/L (< 4.45 ng/mL)
Vitamin B12 < 150 pmol/L (203 pg/mL)
Calcium < 2.15 mmol/L
Vitamin D-25-OH < 50 nmol/L (< 20.8 ng/mL)
Thyroid Stimulating Hormone < 0.3 mU/L
> 4.8 mU/L
Free Thyroxin < 10 pmol/L (< 0.78 ng/dL)
> 24 pmol/L (< 1.86 ng/dL
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confirmed1. Furthermore, we recorded the presence of hypo- or hyperthyroidism at the 
time of diagnosis or its subsequent development during follow up. Prescribed supple-
mentation therapy for hypothyroidism and deficiencies was also noted.
Laboratory investigations performed from 6 months prior to and 3 months after the 
diagnosis were considered as blood tests “at time of diagnosis”. The first year follow up 
blood tests were taken between 9 and 18 months post-diagnosis while the second year 
follow up tests were done within 1.5 to 2.5 years of CD diagnosis, the third year follow 
up between 2.5 and 3.5 years from diagnosis, and so on. If multiple samples for one 
parameter were available at one time period, the most abnormal result was used for 
analysis. If laboratory results were unavailable, they were recorded as missing values. 
Blood samples taken more than 5.5 years after diagnosis were not used for analysis. 
Blood tests done after supplementation of iron or vitamins in order to evaluate treat-
ment effects were not considered in the analysis.
Data analysis
Where appropriate, Pearson’s chi-square test for trend, unpaired t-test and one-way 
ANOVA were used. A two-tailed probability of p < 0.05 was considered significant. Sta-
tistical analysis was performed using Statistical Package for the Social Sciences (IBM, 
version 20; SPSS Inc., Chicago, IL, USA). No approval from a Medical Ethical Committee 
was needed for this study since the blood tests were standard of care and analysis was 
done anonymously.
Results
Patient characteristics are shown in Table 2. There were a total of 182 children evalu-
ated, wherein 119 children were newly diagnosed during the study period. The other 
children were diagnosed prior to 2009 or only had follow-up investigations because CD 
was previously diagnosed in another hospital. The distribution of age, age at CD diagno-
sis, mean follow-up duration, Marsh classification and HLA-typing were similar in girls 
and in boys (data not shown).
Laboratory results
In all participants, 436 blood investigations were performed: 119 times at the time of 
CD diagnosis and 317 times during follow-up visits. On average, 17% of the children had 
incomplete annual blood investigations, where it can further be observed that 58% of 
this group did not have vitamin D tests done.
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At diagnosis
The results of the laboratory tests are shown in Table 3. The mean hemoglobin value 
in the children with ID and IDA was 6.6 mmol/L (SD 0.2). The ten children with IDA were 
Table 2  Characteristics of 182 children with coeliac disease (CD) having medical checks between January 
2009 and December 2014.
Sex, % female 65
Ethnicity, %
European







Age at diagnosis, mean in years (SD) 6.3 (± 4.3)
Duration of follow-up, mean in years (SD) 3.1 (± 3.1)
Diagnosis without biopsies (ESPGHAN criteria), nr 28 
Biopsies confirmed CD, nr 154
Histology small bowel biopsies at diagnosis, %






















CD specific antibodies at diagnosis, %
EMA and/or TG2A positive
EMA and TG2A negative*





^  All with high levels of anti-endomysial antibodies (EMA) and/or anti-tissue transglutaminase type 2 antibodies 
(TG2A).
*  Diagnosis at age 16 months presenting with malabsorption and failure to thrive, small bowel biopsies Marsh 3a  
and (very) good response to a gluten-free diet.
†  CD diagnosed in another hospital, all Marsh 3 proven at biopsy.
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significantly younger than the others (mean 2.64 years SD 1.1; 6.5 years SD 4.3 respec-
tively, p < 0.001). All children showed normalization of their hemoglobin without any 
prescribed iron supplementation a year after a GFD, except for a 3 year old girl whose 
hemoglobin level remained low (6.7 mmol/L) despite supplementation. The mean folate 
level in children with folate deficiency was 7.7 nmol/L (SD 1.4). The age at diagnosis was 
similar among the children with and without folate deficiency (mean age 7.6 years SD 
6.4; 6.2 years SD 4.1 respectively, p = 0.23). Normalization of folate occurred within one 
year after starting the GFD in all folate-deficient children regardless of supplementation 
status. Of note, 40% of the children with folate deficiency were prescribed supplements. 
One child with vitamin B12 deficiency (64 pmol/L) and abnormal homocysteine and 
Table 3  Frequency of deficiencies and thyroid dysfunction in children with coeliac disease at the time of 
diagnosis and during follow-up.
Variable assessed between 













































0/55 0/40 0/44 






0/55 0/40 0/44 














Hypo‡ ‡/hyperthyroidism‡ ‡ ‡ 0/99 0/79 0/73 0/54 0/46 0/47 
Variable assessed between 




















Hypocalcemia± 0/65 0/37 0/34 0/25 0/14 0/31












*  Total number of children at different time points.
#  Ferritin < 12 μg/L in children < 5 years of age or Ferritin < 15 μg/L in older children; ## Iron deficiency plus anemia 
(Hemoglobin < 6.9 mmol/L if age < 7 years, < 6.5 mmol/L if age 7-15 years, < 6.0 mmol/L older children); ^ Folate 
< 10 nmol/L; ^^ Vitamin B12 < 150 pmol/L; ‡ TSH > 4.8 mU/L; ‡ ‡ Free Thyroxin 4 < 10 pmol/L and TSH > 4.8 
mU/L; ‡ ‡ ‡ Free Thyroxin 4 > 24 pmol/L and TSH < 0.3 mU/L.
**  1 girl with normal homocysteine and methylmalonic acid ruling out true vitamin B12 deficiency. ± Calcium < 2.15 
mmol/L; ±± Vitamin D-25-OH < 50 nmol/L.
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methylmalonic acid levels had folate deficiency as well (these tests were performed in a 
referring hospital, thus, the exact data could not be retrieved). Both folate and vitamin 
B12 had normalized six months after their respective supplementations.
Anthropometric evaluation of the children with iron, folate and vitamin B12 deficiencies, 
done in order to see whether these relatively young children had a classic presentation 
of CD with malabsorption, showed stunting (defined as height < -2.0 SDS) and under-
weight (defined as weight for height < -1/5 SDS) in 30% and 15% of the children. In all 
children, recovery of height and weight was seen while on a GFD.
The mean level of vitamin D-25-OH in deficient children was 38 nmol/L (SD 6.8). Only 
25% of these children were prescribed with vitamin D supplements (i.e. calcium carbon-
ate/ vitamin D 500 mg/400 IU, for 3-6 months), yet normalization of values occurred in 
all of these children after one year, except for two adolescents who did not receive these 
prescriptions. The mean age of the children with vitamin D deficiency at diagnosis was 
significantly higher compared to the children with normal vitamin D levels (mean 7.6 ± 
SD 4.6 and mean 5.9 ± SD 4.1 respectively, p=0.03). No child had hyper- or hypothyroid-
ism. Prior to 2009, Graves’ disease and Hashimoto’s thyroiditis were diagnosed in 1 and 
3 patients respectively, both prior to the development of CD. The male-female ratio was 
similar among the children with and without thyroid deficiencies, and with and without 
elevated TSH levels (data not shown).
During follow up
The results of the laboratory tests are shown in Tables 3 and 4. In the first 3 years after 
diagnosis, 3 girls developed IDA (mean hemoglobin 6.6 mmol/L SD 0.2) and 1 girl had per-
sistent IDA (hemoglobin 6.7 mmol/L; She had existing IDA at time of CD diagnosis and it 
continued on despite prescribed iron supplementation post-diagnosis). These girls were 
significantly younger compared to the children without IDA (mean 3.4 years SD 1.4, and 
6.5 years SD 4.3, at time of IDA respectively, p = 0.02).The hemoglobin and ferritin levels 
normalized in the rest of the girls within 1 year of CD diagnosis. Iron supplementation 
was only given to one of these patients.
Two patients (3%) developed mild folate deficiency (folate levels 8.7 and 9.5 nmol/L) dur-
ing the second follow-up year. Supplementation was given to one of them, a 12-year old 
boy, with normalization of folate after 6 months. Supplementation was withheld in the 
other patient, a 17 year old asymptomatic girl, since her folate level was only marginally 
low (9.5 nmol/L). Her follow-up measurements could no longer be obtained after she 
transferred to the gastroenterology department of another hospital. One adolescent had 
low vitamin B12 at the first and second year visits, but since normal levels of homocys-
teine and methylmalonic acid were found, true vitamin B12 deficiency was ruled out and 
no supplementation was thus prescribed.
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Vitamin D deficiency (mean vitamin D-25-OH 38.5 nmol/L, SD 7.7) was present in up 
to 25% of the patients. Calcium carbonate/ vitamin D, once daily 500 mg/400 IE, was 
prescribed in 40% of deficient children, with the levels returning to normal in a third of 
these children.
No hyper- or hypothyroidism was found during our follow-up period. However, a 10 year 
old asymptomatic girl, whose mother was known to have hypothyroidism due to a rare 
TSHR-gene mutation (C.1631G>A), was diagnosed with subclinical hypothyroidism sec-
ondary to the same genetic defect (FT4 11.8 pmol/L; TSH 12.8 mU/L). Elevated TSH levels 
(mean 6.2, range 4.8-13.6, SD 1.6) were seen in 33 patients. It was noted to occur once 
Table 4  Summary of the literature on the prevalence of iron, vitamin B12 and folate deficiency in coeliac 
disease patients*.






Nutrient deficiency**  
at diagnosis
Nutrient deficiency during 
follow-up
Bonamico M39 1987 Children 80 Iron deficiency (56%) Not available
Dahele A40 2001 Adults 39 Iron deficiency (49%)
Vitamin B12 deficiency (41%)
Vitamin B12 deficiency resolved 
after one year gluten-free diet
Kemppainen T41 
1998
Adults 40 Folate deficiency (35%)
Iron deficiency (32.5%)
Folate and iron deficiency 8%  
and 22.5% after one year gluten-
free diet respectively
Dickey W42 2002 Adults 159 Vitamin B12 deficiency (12%) Not available
Haapalahti M18 2005 Adolescents 
and young 
adults
26 Iron deficiency (28%)
Folate deficiency (31%)




Adults 132 Iron deficiency (34%) 30% “some degree” of iron  
deficiency after one year with GFD







73 Iron deficiency (45%) Not available
Wierdsma NJ21 2013 Adults 80 Iron deficiency (46%)
Folate deficiency (20%)
Vitamin B12 deficiency (19%)
Not available 
Gokce S44 2014 Children 191 Iron deficiency (8%) Not available
*  By means of Medline search from 1980 until December 2014 using coeliac disease, anemia, iron deficiency, folate 
deficiency, vitamin B12 deficiency, nutritional deficiencies and nutritional status as Mesh terms.
**  Defined as levels of hemoglobin, ferritin, folate and vitamin B12 below reference values.
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in 48% of them and repeatedly in 39% . The high TSH values only normalized in 17% of 
these patients. However, all children with repeatedly elevated TSH levels had negative 
thyroperoxidase antibodies (AbTPO). Two patients developed hypothyroidism after the 
5th year of CD follow-up. Both children complained of fatigue and showed decelerating 
growth. By accounting for thyroid dysfunction prior to CD diagnosis and beyond our 
follow-up period (after 5.5 years of follow-up), the prevalence of hypothyroidism in our 
cohort was 3.2% (n=6, 4 female) and hyperthyroidism, 0.5% (n=1, male).
Discussion
As far as we know, this is the first study on the outcome and relevance of complemen-
tary blood investigations in the follow-up of children with CD. The results indicate that 
these investigations are relevant at the time of diagnosis because up to 28% of the 
children presented then with varying iron, folate and vitamin B12 deficiencies. However, 
ordering these tests at patient follow-up visits may be questionable since only mild de-
ficiencies occurred in a minority of the children (5-10%). This outcome has implications 
in the organization of care for CD children because blood tests are time-consuming 
and expensive. As of 2014, this costs approximately €150-200 per patient, merely for 
extracting and handling blood samples in our laboratory, and exclusive of coeliac serol-
ogy charges.
There is limited information on the incidence of nutritional deficiencies in patients with 
treated CD. Published data vary widely, most probably because they have evaluated 
small and heterogeneous patient groups focusing on certain nutritional deficiencies, 
only at time of diagnosis (Table 4). In general, the nutritional deficiencies at diagnosis 
found in our study were noted to occur similarly or even less frequently than earlier 
studies, except for vitamin B12 deficiency. This deficiency was seen to be much lower in 
our cohort (2% versus 12-41% found in adolescents and adults)18-21. The absence of IDA, 
folate and vitamin B12 deficiency during follow-up may be explained in two ways. First, 
adherence to the GFD leads to recovery of the intestinal mucosa, thereby normalizing 
nutrient absorption. Second, dietary counselling is offered to the patients after diagno-
sis. This includes daily nutritional intake of iron, folate and vitamin B125. Interestingly, a 
recent study in adult CD patients showed an increased use of over the counter supple-
ments simultaneous with a GFD treatment22, something that we did not investigate 
in our cohort. In the Netherlands, over the counter use of supplements in children is 
uncommon. Dietitians, whose role is to provide advice on GFDs, likewise do not pro-
mote its use. However, the fact that we only recorded prescribed supplements may have 
underestimated the prevalence of deficiencies at follow-up.
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ID and IDA were infrequently seen during follow-up visits. These values were consider-
ably less compared to the rest of the children from the general Dutch population aged 
6-36 months. In the latter group, the frequency of ID was 18.8% and IDA, 8.5%23. More-
over, the frequency of ID in our patients is lower than the reported 17% among healthy 
Finnish adolescents18. Therefore, it may be questioned whether these deficiencies are 
related to CD or merely reflect its presence in the general child population .
Our findings on the frequency of thyroid dysfunction (3.7%) are similar to the ones from 
previous studies, with the prevalence of thyroid autoimmunity (elevated TSH or pres-
ence of AbTPO), hypothyroidism and hyperthyroidism varying from 10-26%24,25, 2-6%24,25 
and 1%, respectively24,25. The rationale behind thyroid function testing as part of a CD 
patient’s follow up rests on the fact that there exists a high frequency of thyroid autoim-
munity in CD24,26. In addition, there is conflicting evidence on the GFD’s protective effect 
in the development of auto-immune thyroid disease27,29. However, the clinical relevance 
of elevated TSH is debatable since elevated TSH levels can fluctuate or normalize, as 
was seen in our patients. They were also observed to occur or persist, in the absence of 
AbTPO and without the development of clinical hypothyroidism. Furthermore, thyroid 
disease was only diagnosed in symptomatic children whose family history and clinical 
presentation were suggestive of hypo-/ hyperthyroidism.
The strength of our study is the relatively large patient group with well-documented 
CD, most likely representative of the West European pediatric CD population. The long 
follow-up period allowed us to demonstrate the natural course of nutritional deficien-
cies after treatment with a GFD.
One limitation of our study is an incomplete annual laboratory measurement, despite 
its availability in the majority of cases. Most missing laboratory investigations occurred 
due to insufficient blood obtained at venipuncture. We believe that since the analysis of 
calcium and vitamin D took place in a large group of patients within a short follow-up 
period, the values obtained represent the general population of coeliac children.
One could argue that deficiencies during follow-up might reflect non-compliance to the 
GFD and therefore, a degree of malabsorption. We have thus retrospectively examined 
the TG2A levels in children with IDA and folate deficiency and found them all to be nor-
mal, thus confirming the patient compliance.
It is known that CD can lead to a diminished bone mineral density in 40-66% of the coeli-
ac patients at diagnosis30,31, with low calcium levels in 18-24%31,32. In coeliac children and 
adults, a GFD has proven to be effective in ameliorating bone mineralization31,33. Vitamin 
D deficiency has been found to equally occur at diagnosis and during follow-up32,34; this 
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is similar to our results. It is known that vitamin D deficiency occurs in up to 20-70% of 
children, regardless of age, sex, socio-economic status and dietary supplementation. The 
main variation in its occurrence may easily be explained by race or ethnicity and seasonal 
influences, i.e. it is more commonly observed among darker individuals owing to differ-
ing skin pigmentation and in the winter due to reduced sun exposure35-38. Our analysis 
indicates that vitamin D status depends on more than a gluten-free diet and supple-
mentation, considering that 2/3 of patients who were prescribed supplements to correct 
vitamin D deficiency still did not achieve normal levels. Therefore, it seems that vitamin 
D deficiency may not be directly linked to CD, but merely represents its frequency in 
the general population. However, assessment of vitamin D status and correcting the 
deficiency or ensuring its spontaneous resolution can be generally considered as good 
patient care because of the known effects of untreated CD on bone health.
Conclusion
We have shown that at the time of pediatric CD diagnosis, iron deficiency, iron deficien-
cy anemia, and folate deficiency occur frequently. However, the vast majority of these 
values normalize after a GFD treatment, even without the prescribed supplementations. 
The low frequency of deficiencies at follow-up may not even be related to CD, since they 
are also found to the same degree in the general pediatric population. Furthermore, we 
have shown that vitamin B12 deficiency only sporadically occurred at the time of CD 
diagnosis, whereas hypocalcemia did not occur at all. Presence of thyroid disease in our 
cohort was low and occurred only in symptomatic children. We therefore recommend 
that these variables only be evaluated on indication in follow up CD visits, for example, 
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Assessment of dietary compliance 
in coeliac children using a 
standardized dietary interview











backgrOund & aIMs Compliance to a gluten-free diet (GFD) in coeliac disease (CD) 
is ideally assessed by dietary interviews, albeit time-consuming. Short dietary question-
naires have been developed for adults but not for children. Primary aim was to compare 
GFD compliance in coeliac children, measured by a short dietary questionnaire against 
a dietary interview. Secondary aims were correlation between both questionnaires and 
coeliac antibodies and identifying variables predicting noncompliance.
MethOds Between 2012 and 2014, participants in the eHealth CoelKids study, com-
pleted a short dietary questionnaire and standardized dietary interview together with 
measurement of anti-tissue transglutaminase antibodies (TG2A). Results of the question-
naires were assigned under similar categories. Factors possibly influencing dietary com-
pliance were recorded. Where appropriate, Pearson’s Chi-square test for trend, unpaired 
t-test, Cohen’s kappa and one-way ANOVA were used.
results 151 of 165 participating patients were studied, 66% were female. Mean age 
was 11.3 years (2-26, SD 5.4), mean age at CD diagnosis was 4.9 years (1-23, SD 4.0). 
The short questionnaire and dietary interview correlated poorly, detecting problems in 
dietary adherence in 14% and 52% of the patients, respectively (Cohen’s kappa 0.034). 
Only the short questionnaire correlated with TG2A (p = 0.003). Only older age was as-
sociated with noncompliance, the mean age of completely nonadherent, adherent but 
committing errors, and strictly adherent patients were 15.5, 11.5 and 10.1 years, respec-
tively (p<0.001).
cOnclusIOn Compared to the dietary interview, short dietary questionnaires and 
TG2A serology failed to detect dietary transgressions in CD children, wherein adoles-




Coeliac disease (CD) is an immune-mediated systemic disorder elicited by gluten in 
genetically susceptible individuals and is characterized by anti-tissue transglutaminase 
type 2 antibodies (TG2A) and enteropathy1. In individuals carrying the HLA-DQ2 and/or 
DQ8 haplotype, the ingestion of gluten (a group of proteins present in cereals such as 
wheat, barley and rye, can lead to a T cell-initiated inflammatory response, damaging 
the small bowel mucosa2. CD is a common disorder, occurring in approximately 1-3% of 
the general population3,4.The disease has a variable clinical presentation, ranging from 
malabsorption with diarrhea, abdominal distention and weight loss, to nonspecific signs 
and symptoms such as fatigue, osteoporosis or iron deficiency anemia. CD can be diag-
nosed by the detection of CD-specific antibodies (usually IgA class tissue transglutamin-
ase antibodies TG2A and anti-endomysium antibodies)5,6 and small bowel biopsies that 
show characteristic histological alterations. CD can be successfully treated in most cases 
with a gluten-free diet (GFD) which restores small bowel histology and improves symp-
toms. However, this diet may be difficult to follow and may lead to social constraints. It 
is known that dietary adherence differs among individuals, with noncompliance varying 
from 25-50%7-9 among children and adolescents. Despite the absence of a gold standard 
to assess dietary compliance10, a dietary evaluation by a trained dietitian is considered 
the best method11. Repeat duodenal biopsies to monitor mucosal recovery is usually not 
a practical option, especially in children wherein endoscopy to obtain biopsies is done 
under anesthesia or deep sedation. Serologic testing is not sensitive enough to detect 
infrequent gluten exposure12-14. It has been shown that adults tend to overestimate their 
level of compliance if they are asked to self-report it15. Furthermore, information about 
the trustworthiness of adherence as reported by parents show a broad range16. Food 
diaries and questionnaires are frequently used in CD research in order to estimated 
gluten intake. These are, however, mostly used in order to assess the diet’s nutritional 
content17,18 and have not been validated, except for food questionnaires in infants19 and 
children aged 1-4 years20. A dietary interview to assess compliance is time-consuming, 
taking 20-30 minutes per patient, and requires expert personnel. Several short ques-
tionnaires have been developed to measure GFD adherence in order to save time and 
address compliance in a standardized manner. For example, a questionnaire developed 
in Italy and tested in coeliac adults13 consists of four questions that take less than a 
minute to administer. Moreover, it may be filled out even by non-expert personnel or by 
patients themselves online. To our knowledge, these short questionnaires have never 
been tested in children, adolescents or young adults.
The primary aim of this study was to compare GFD compliance in CD children, ado-
lescents and young adults as measured by a short and standardized dietary question-
naire that has been validated in coeliac adults13 against a standardized dietary interview. 
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Secondary aims include 1. the assessment of the correlation between the short dietary 
questionnaire, standardized dietary interview and coeliac-specific serum antibodies, 
and, 2. the identification of risk factors for noncompliance with the gluten-free diet.
Materials and methods
For this cross-sectional study, dietary compliance was assessed in coeliac children and 
young adults participating in the eHealth CoelKids study and who were randomized to re-
ceive the usual health care (www.coelkids.nl). Patients were recruited between May 2012 
and July 2014. They became eligible if CD was diagnosed according to ESPGHAN criteria1,21 at 
least 1 year before enrolment and patients (or their parents) could complete the online ques-
tionnaires in Dutch. As part of the CoelKids project, the patients and/or parents were asked 
to complete two questionnaires about dietary compliance. The first questionnaire consisted 
of a Dutch adaptation of a short questionnaire validated in Italian CD adults to assess GFD 
compliance, hereafter referred to as the “short questionnaire”13 (Figure 1) in this article.
‘Often’: the patient consumes gluten quite frequently that he/she cannot remember 
when and how many times that has happened. ‘Rarely’: the patient consumes gluten 
only occasionally. She/he can remember when and how many times that has happened.
Figure 1 Short diet questionnaire validated in coeliac adults13















Do you check the labels of packaged food?
When you eat out, do you tell the person  
who is cooking about your disease?
Do you only eat packaged food guaranteed  






The scores obtained from this questionnaire were divided into three scores: 1 — indicating 
GFD not followed, 2 — GFD with important errors, 3 — strict GFD. The second question-
naire, hereafter referred to as the “dietary interview questionnaire”, consisted of an ex-
tensively written patient interview developed by one of the authors (EH) who is an experi-
enced dietitian specializing in CD and GFD. This 26-item questionnaire reflects the patient 
interview that was verbally conducted during regular face-to-face consultations with the 
dietitian to evaluate the GFD (Supplemental material appendix C). This interview was 
standardized and converted into a written version for this project. It addresses several do-
mains, including GFD compliance and patient (or parent) knowledge and attitude toward 
the GFD. For example, they were asked about gluten-free food preparation, the reading of 
food labels, and the need for extra information/ contact with a dietitian or medical doc-
tor. For optimal comparison, the final scores of the dietary interview questionnaire were 
grouped into the same three scores obtained from the short questionnaire. In addition, to 
improve user-friendliness, a comprehensive 11-item version of the dietary interview was 
also tested (Supplemental material appendix C).
The questionnaires were completed after a regular patient (and parent) outpatient visit 
for CD follow up. The questionnaires were filled out by the parents if the child was 
younger than 12 years or by the parents and child together if the child was older than 
12. Since the visit was a regular medical check for CD, coeliac-specific antibodies in the 
serum were tested according to (inter-)national CD guidelines22,23. The Coelkids study 
protocol was approved by the Medical Ethical Committee of LUMC and by the respective 
boards of each participating center and complied with Good Clinical Practice guidelines 
(registration in the Dutch Trial Register, NTR3688, www.trialregister.nl).
Data management and statistics
The responses to the questionnaires were entered by the participants themselves into a 
secure web-based data management application (NEN7510 certified). Patient character-
istics such as age, age at CD diagnosis and sex were recorded, as was their serum TG2A at 
the time of questionnaire completion. Pearson’s Chi-square test for trend and unpaired 
t-test and one-way ANOVA were used where appropriate. Cohen’s kappa was used to 
measure inter-rater agreement for the two questionnaires. A two-tailed probability of p 
< 0.05 was considered significant. Analyses were performed with SPSS software (version 
20.0, IBM Corp. Armonk, New York).
Results
In total, 151 of 165 children and young adults completed both questionnaires on dietary 
compliance. Patient characteristics are shown on Table 1.
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The results of the short questionnaire and the dietary interview questionnaire do not 
correlate with each other since dietary adherence problems (scores 1 and 2) were re-
ported by 52% (n=78) and 14% (n=21) of the patients when using the dietary interview 
questionnaire and the short questionnaire, respectively (Cohen’s kappa 0.034) (Table 2).
Table 1 Characteristics of the 151 participating children and young adults with coeliac disease (CD)
Age (years), median (IQR) 10.2 (7-14)









Female, no. (%) 100 (66%)
Age at diagnosis of CD (years), median (IQR) 3.8 (2-7)
Duration of CD (years), median (IQR) 5.3 (3-8)
Anti-tissue transglutaminase type 2 antibodies (TG2A) measured, no. (%) 145 (96%)
TG2A positive*, no. (%),
Mean TG2A level if positive, in U/mL (range)
14 (10%)
20.6 (7-56)
Being on another diet in addition to gluten-free diet, no. (%) 9 (6%)
Other family members present with CD, no. (%) 45 (30%)
Expected complaints after eating gluten containing food, no. (%) 39 (26%)
* Cut-off of normality >7 U/ml
Table 2  Inter-rater agreement between the short gluten-free dietary adherence questionnaire and dietary inter-
view, tested in children, adolescents and young adults with coeliac disease, measured by Cohen’s kappa.
Dietary compliance Short questionnaire
Standardized 
interview
Score 1  
(non- adherent)
Score 2 (adherent 
but with errors)
Score 3  
(strictly adherent)
Total
Score 1  
(non- adherent) 11 0 6 17
Score 2 (adherent 
but with errors) 3 0 58 61
Score 3  
(strictly adherent) 6 1 66 73




TG2A were measured in 145 patients wherein 10% of them turned out to be positive. 
Sex and age at the time of questionnaire completion were similarly distributed among 
the patients with positive and negative TG2A levels (64% and 66% female, p = 0.87; and 
10.6 and 11.0 years, p = 0.79, respectively). However, patients with positive TG2A were 
significantly older at the time of diagnosis and had been treated with a GFD for a shorter 
period of time when the questionnaires were filled out (6.5 and 4.3 years, p = 0.017, and 
4.1 and 6.8 years, p = 0.042, respectively). Positive TG2A results were mostly seen in 
children 2-6 years of age as well as among adolescents and young adults >16 years (both 
groups 15%). As shown in Table 3, only the results of the short GFD questionnaire were 
significantly associated with the presence of a positive TG2A, which was found in 35% 
(n=6) of the patients with self-reported noncompliance (n=17) versus 6% of the patients 
who reported good adherence (n=8 out of 127 patients, p=0.003).
Older age was the only factor significantly associated with noncompliance, with mean 
ages of 15.5 , 11.5 and 10.1 years for patients who were completely non-adherent to the 
diet, those who adhered but committed errors, or those who strictly adhered, respec-
tively (p<0.001). Compliance to the GFD diet was best in children younger than 6 years 
of age, with strict dietary compliance (score 3) in 74% of them, and without any child 
Table 3  Distribution of anti-tissue transglutaminase type 2 serum antibodies (TG2A) levels in 145 coeliac 
patients according to the results obtained from the gluten-free diet (GFD) adherence questionnaires.
Short dietary
questionnaire†




1 Non adherence 17 6 35
p = 0.0032 Errors 1 0 0
3 Good adherence 127 8 6
Standardized 
dietary interview†




1 Non adherence 14 3 21
p = 0.1912 Errors 59 6 10
3 Good adherence 72 5 7
* Cut-off normality >7 U/ml
†  Score of 1 reflecting non-adherence to a GFD, 2 reflecting adherence to a GFD but with errors that require 
correction, and 3 reflecting strict adherence to a GFD.
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in the totally non-adherent group (score 1). Sex, age at CD diagnosis and the presence 
of other family members with CD did not influence GFD compliance (data not shown), 
nor did being on another diet in addition to the GFD (data not shown) or the presence of 
complaints after gluten ingestion.
Since the results of the short questionnaire did not correlate with that of the dietary in-
terview questionnaire, we modified the latter to become more comprehensive and user-
friendly. To achieve this, the items of the dietary interview questionnaire were separately 
weighed using item-total correlation, with regard to their contribution to the score. This 
resulted in reduction of the total number of items from 26 to 11. For reproducibility and 
verification, this modified questionnaire was tested in the 158 coeliac children and young 
adults of the eHealth intervention group of Coelkids, who also completed the short diet 
questionnaire and the dietary interview questionnaire. Sex, age and disease duration at 
time of questionnaire completion were similar in the Coelkids intervention and control 
group: 69 and 66% female, 11.0 and 11.4 years and 6.9 and 6.7 years, respectively. As 
shown in Table 4, there was a moderate correlation between the results of self-reported 
dietary adherence as assessed by the dietary interview questionnaire and the adapted 
questionnaire with 11 items (Cohen’s kappa 0.56). All patients who reported to be totally 
non-adherent the GFD by using the dietary interview questionnaire (n=14) also reported 
as non-compliant upon completing the adapted 11-item questionnaire. However, discrep-
ancies in self-assessed dietary adherence were observed in 24% of the patients (n= 38).
Tabel 4  Inter-rater agreement between the long gluten-free diet adherence questionnaire, tested in children, 
adolescents and young adults with coeliac disease, and its modified gluten-free diet score, measured 
by Cohen’s kappa.
Dietary compliance Modified score
Standardized 
interview
Score 1  
(non-adherent)
Score 2 (adherent 
but with errors)
Score 3  
(strictly adherent)
Total
Score 1  
(non- adherent) 14 0 0 14
Score 2 (adherent 
but with errors) 0 35 22 57
Score 3  
(strictly adherent) 0 16 71 87





Although GFD is the only effective therapy for CD, guidelines that assess dietary adher-
ence do not exist for either adults or children. By using a standardized dietary interview 
questionnaire in this study, we found a high percentage (52%) of children, adolescents 
and young adults who followed the GFD, but they did so with errors or did not follow 
the diet at all. In 40% of these coeliac patients, dietary transgressions would have been 
unnoticed if dietary adherence were only assessed using CD-specific serology and the 
short dietary adherence questionnaire validated in adults. This short questionnaire has 
proven to have a good correlation with serum levels of coeliac-specific antibodies in 
adults13 and in children during their first year of starting a GFD24. Our results however 
show that patients may have negative TG2A serology, yet do not strictly adhere to the 
diet when using the long questionnaire derived from the dietary interview. This discrep-
ancy between GFD adherence and results of CD serology has been previously demon-
strated, both for EMA and TG2A9,25,26 and indicates that measurement of CD-specific 
antibodies is not a sensitive tool to detect problems in dietary adherence24. One of the 
main differences between the short GFD adherence questionnaire and the dietary in-
terview questionnaire is that the latter addresses practical issues possibly leading to 
errors related to the GFD such as storing gluten-free products at home separate from 
gluten-containing food, and preparing gluten-free food with separate kitchen utensils. 
These issues address the actual daily risk of gluten consumption. Despite our efforts, we 
were unable to reduce the length of the dietary interview questionnaire. However, with 
the increasing use of electronic patient records and eHealth tools, completing ques-
tionnaires before or during a medical consultation should be easily implemented in the 
health care for children and young adults with CD. In addition, we expect that this will 
contribute to improvement of care for CD patients by, on the short term empowering 
them, leading to a better diet adherence, and possibly, on the long-term, by avoiding 
complications of their disease. If a better dietary assessment will also result in improve-
ment of symptoms can only be investigated in (future) prospective studies.
One of the strengths of this project is the prospective design and the relatively large group 
of patients included. All participants completed the questionnaires and TG2-serology was 
available in 96% of them. Our cohort seems representative for CD children and young 
adults, including the decreased dietary compliance in adolescents; an established fact in 
CD populations8,27.
One may argue that since the dietary interview questionnaire was designed with the 
purpose of this project in mind, without previous validation, it might not accurately 
demonstrate problems with GFD compliance. The questionnaire, however, was devel-
oped by an experienced dietitian who has worked extensively with coeliac patients. It 
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therefore reflects the patient encounter and contains the same questions asked during 
this dietetic consultation. Furthermore, completing the standardized dietary question-
naire by patients avoids omissions that may occur during face-to-face consultations, 
for example, due to insufficient time. A possible limitation could be the fact that we 
also included CD patients who had been on a GFD for only 1 or 2 years. In our opinion, 
the first year on a GFD is intense and essential to learn how to adhere to the diet (with 
regard to shopping, reading etiquettes, contamination etc). Therefore, face-to-face con-
tact seems to be more adequate than questionnaires. One could argue that CD specific 
serology might not have normalised in the first 1-2 years on a GFD, thus impeding the 
correlation between serology and the questionnaires. However, it has been shown that 
TG2A normalisation occurs after 12 months on a GFD in the majority of children28, there-
fore limiting this effect.
Recent developments in diet monitoring include a new method of measuring gluten 
immunogenic peptides in the stool and urine29,30, which seem to enable direct and 
quantitative assessment of gluten ingestion. However, its future role needs to be more 
extensively evaluated because result manipulation by gluten avoidance prior to testing 
is possible since gluten immunogenic peptide analysis only detects gluten if ingested a 
few days before testing.
In conclusion, our results show that dietary adherence should be assessed by a dietary 
interview in combination with specific CD antibodies determination. Available short 
 dietary questionnaires and TG2A serology alone do not detect all errors in GFD adher-
ence in children and young adults. A standardized dietary questionnaire reflecting the 
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Due to the association of coeliac disease and HLA-specificities DQ2 and DQ8, HLA-typing 
can be used for risk determination of the disease. This study was designed to evaluate 
the knowledge of parents from coeliac families regarding HLA-typing and the impact of 
HLA-typing on the perception of the health of their children. A structured questionnaire 
was sent to the Dutch, Spanish and German parents participating with their child in the 
European PreventCD study on disease prevention in high-risk families, addressing par-
ents’ understanding of, and attitude towards HLA-typing, distress related to HLA-typing 
and perceived health and health related quality of life of their children. 68% Of parents 
of 515 children returned the questionnaires with 85% of children being DQ2/DQ8 posi-
tive. The majority of all parents answered the questions on knowledge correctly. 48% 
Of parents of DQ2/DQ8 negative children thought their child could develop coeliac dis-
ease. More distress was reported by parents of DQ2/DQ8 positive children (p<0.001). All 
parents showed few regrets and would repeat HLA-typing in future children. Perceived 
health and health related quality of life were similar. 
cOnclusIOn We can say that misinterpretation of DQ2/DQ8 negative results by par-
ents is frequent. DQ2/DQ8 positive results do not affect perceived health and health 
related quality of life of children, but may cause temporary negative feelings among par-




Coeliac disease (CD) is the most common intolerance to a dietary component in children 
and adults1. In genetically predisposed individuals, CD is precipitated by the ingestion of 
gluten, which are storage proteins in wheat (gliadin), rye (secalin) and barley (hordein)1,2. 
T-cells in the lamina propria of the small intestines recognize the gluten peptides when 
they are bound to the Human Leukocyte Antigen (HLA) class II specificities -DQ2 and/
or -DQ8 on antigen presenting cells2. Screening for CD can be done by measuring CD 
specific antibodies against the enzyme tissue transglutaminase type 2 (anti-TG2A), en-
domysium (EMA) and deamidated gliadin peptides3. CD is treated with a gluten-free 
diet. Long term complications of untreated CD are among others diarrhea, abdominal 
pain, perinatal problems, osteoporosis, and cancer1,4.
CD has a strong genetic component, since 90% of CD patients carry the class II HLA-
DQ2 haplotype, about 5% the HLA-DQ8 molecule5-8 and the rest usually the half of the 
HLA-DQ2 heterodimer.
The HLA-DQ2 and DQ8 haplotypes are present in over 25% of the general population6, 
but only 1% actually develops CD1. This indicates that HLA-DQ2 and -DQ8 haplotypes are 
necessary, but not sufficient for disease development. Around 40% of the heritability of 
CD is explained by HLA-DQ2 and/or -DQ8. First degree family members of CD patients 
who are HLA-DQ2 and/or DQ8 positive (DQ+) have an increased risk of approximately 10% 
to develop CD9. Because of the high negative predictive value of HLA-typing for develop-
ment of CD, unnecessary invasive investigations (i.e. blood punctures, duodenal biopsies) 
in HLA-DQ2 and DQ8 negative (DQ-) individuals can be avoided. Consequently, pediatri-
cians can offer HLA-typing to first-degree family members of a child diagnosed with CD10.
Being diagnosed with CD may have impact on patients’ Health Related Quality of Life 
(HRQoL)11,12. Currently, concerns are raised about the impact on parents of genetic test-
ing for chronic diseases which only provide a crude estimate of disease risk. It is known 
that the attitude of parents towards genetic testing for common preventable health con-
ditions in their children is moderately positive13. Unfavorable results may cause parental 
concerns about the lifelong increased risk for development of CD and the bond between 
child and parents might be affected with the development of a sense of vulnerability 
and protectiveness of the child, despite the child’s good health14. To our knowledge, the 
parental impact of HLA-typing for CD risk determination has not been studied. Our aim 
was to investigate the effect on parents from families with high risk for CD of HLA-typing 
in their healthy children. We expected parents whose children are DQ+ to take on a more 
adversary position towards HLA-typing. Subsequently, we hypothesized that parents of 
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DQ+ children will interpret more of their children’s symptoms as a sign of CD, and will 
have a higher rate of health care utilization.
Patients and Methods
For this descriptive study we took advance of the Dutch, Spanish (Reus) and German 
cohorts of the ongoing European family study investigating the prevention of CD, Pre-
ventCD (www.preventcd.com). The PreventCD study investigates the possibility of re-
ducing the frequency of CD by introducing small quantities of gluten to infants, be-
tween 4-6 months of age, preferably while they are being breast-fed. In families with a 
diagnosed CD member, newborns were HLA-typed shortly after birth and if they were 
positive for HLA-DQ2, DQ8 or half of the DQ2 allele, they were considered HLA-DQ+ and 
included in the study (hereafter referred to as PreventCD children)15. After informing the 
parents, the result of the HLA-typing was sent as a letter with an individual risk score: 
no risk if DQ-, 10% risk if DQ+. In addition, HLA-typing was offered to parents and sib-
lings of the PreventCD children.
For this study, the parents were asked to fill in a questionnaire in their native language 
after receiving the HLA-typing results. Parents of children who had developed CD prior 
to sending the questionnaire were not invited to participate. Parents attending the hos-
pital in Israel with their in PreventCD participating children were also asked to complete 
the questionnaire. Since no information could be obtained about the Israeli participa-
tion rate, the results on these children and parents were not used in the main analysis.
Questionnaires
Most questions were weighed on a Likert scale.
Parents’ knowledge on HLA-typing for CD was assessed by the following true-false 
questions: 1. All children that have HLA-DQ2 and/or DQ8 will develop CD (incorrect) and 
2. A healthy person can be carrier of HLA-DQ2 and/or DQ8 (correct). Good knowledge 
was defined as answering both correctly. To assess parents’ understanding of the HLA-
typing results of their child, they were asked to evaluate its risk to develop CD.
Since there was no HLA-Impact questionnaire available, we constructed one consisting 
of a form based on validated questionnaires concerning genetic testing for hereditary 
blood diseases16 and cystic fibrosis17. The attitude of the parents towards HLA-typing 
was evaluated by asking them about the reliability, possible regrets and whether they 
would consider HLA-typing in case they would have another child . Furthermore, par-
ents rated the information they received on HLA-typing on a scale from 1 (“very bad”) 
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until 10 (“excellent”). Parents’ behaviour after receiving the HLA-typing results of their 
children was assessed by the frequency of discussing the results with friends or family 
and by the methods used to get additional information on HLA-typing, e.g. internet, 
patient association et cetera. Parental feelings after receiving the HLA-results were as-
sessed by 5 questions concerning the degree of worries, anxiety, unhappiness, reassur-
ance and relieve. A total score reflecting these feelings (min 0-max 5, high score indi-
cating positive feelings) was calculated. To assess the parental mood in the week prior 
to the questionnaire we used a 4-item Hospital Anxiety and Depression Scale (HADS)18 
subscale, a high score corresponding with a positive mood. Internal consistency for all 
scales was evaluated with Cronbach’s alpha.
Perceived health of the children was assessed by questions about the frequency of diar-
rhoea, vomiting, abdominal distension, constipation and fatigue in their child in the last 
3 months. Parents were asked about the concerns about their children’s health, and 
how often their children had been ill in comparison with other children. The health care 
utilization was assessed by the frequency of medical visits of the child during the last 
month. Frequent consultation was defined as 2 or more visits monthly.
Health related quality of life (HRQoL) of the children was evaluated with the validated 
TNO-AZL Preschool Children Quality of Life Questionnaire (TAPQOL) 43-item version19.
Data management and analysis
Parents in the Netherlands, Spain and Germany received an e-mail with an invitation 
to participate accompanied by a personal digital code, which gave access to the online 
questionnaire. A paper version was also available if requested. They were also asked to fill 
in the questionnaire about their HLA-typed children not participating in PreventCD, but 
only with regard to the child specific part. The online questionnaire was designed as a web 
form in a secure data management application ProMISe, (www.msbi.nl/promise), with 
automatic data export to the Statistical Package for Social Sciences (SPSS) version 20.0.
Scale reliability of the HADS items and the negative feelings after receiving the HLA-
typing result were calculated with SPSS. For statistical analysis of the HLA-Impact ques-
tionnaire, the Pearson’s Chi-square test for trend, the unpaired t-test, Kruskall-Wallis and 
Mann-Whitney U test were used where appropriate. For the TAPQOL, a score ranging 
from 1 to 100 was calculated for every domain, a higher score reflecting a better HRQoL 
in the relevant scale19, 20. Due to abnormal distribution of the TAPQOL results, we used 
the Mann-Whitney U test for statistical analysis of the results. For each questionnaire 
item, a difference was found significant if p < 0.05.
This study was approved by the Medical Ethics Committees of all the participating centers.
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Results
The characteristics of the participating children and parents are presented in Table 1. 
The age, sex, parent completing the questionnaire, parental educational level and time 
between receiving the HLA-typing result and completing the questionnaire were similar 
among the HLA negative and positive children (data not shown).
Both parents of DQ+ and DQ-children had a good knowledge on HLA-typing in CD (88% 
and 93% respectively) and they found HLA-typing a “reliable” test (88% and 93% respec-
tively). However, when asked about the chance of their own child to develop CD according 
to his/her HLA-typing, 48% of the parents of the DQ- children thought their child still had 
a chance to develop CD (Figure 1). There was no correlation between this perception by 
the parents and their opinion about the reliability of the HLA-test (data not shown).
Table 1  Distribution of characteristics of children and parents and of parental attitude and knowledge of 
HLA typing and CD.
Netherlands Germany Spain Total
Children (nr) 214 181 91 486
Participation (%) 85 62 59 72
Age children (mean, years) 3.2 4.1 5.0** 3.8
Sex children (% male) 49 53 52 51
Questionnaire filled in by mother (%) 88 89 74 86
Educational level parents high* (%) 82 81 65 79
Children HLA DQ2 and/or DQ8 positive (%) 86 80 93 85
Time between HLA-result and questionnaire (mean, years)** 2.4 2.8 4.4** 2.8
Knowledge of HLA-typing: Both questions answered correctly (%) 97** 87 92 92
No regrets about HLA-typing (%) 98 100 97 99
Parents would repeat HLA-typing in future children (%) 98 97 94 97
Perception of given information about HLA-typing as good (%) 89 86 67 85
Searched for extra information about HLA-typing (%) 31 38 39 34





No parents of DQ- children had regrets about HLA-typing and all of them would perform 
HLA-typing in their child if they would have one later on. Likewise, almost all parents of 
DQ+ children (99%) did not regret HLA-typing in their children and 97% of them wanted 
HLA-typing in their child if they would have one in the future. The information about 
the HLA-typing was similarly appreciated by the parents of DQ- and DQ+ children with 
scores of 8.1 and 8.0 respectively on a 1-10 scale. The majority of parents found the 
information on HLA-typing to be “sufficient, clear and complete” (76% and 87% of par-
ents of DQ- and DQ+ children respectively). Parents who received unfavourable results 
looked for more information on HLA-typing (38% vs. 17%, p = 0.01), with the Internet 
mentioned most frequently. HLA-typing results were discussed equally with family and 
friends in both groups (57 and 67% DQ- and DQ+ respectively). The knowledge of HLA 
typing and CD, the attitude towards HLA-typing and the information about it among the 
different countries is shown in Table 1.
Significantly more negative feelings were reported by parents who received unfavour-
able HLA results (mean 3.4, SD 0.9) compared with those receiving favourable results 
(mean 4.6, SD 0.6) (p<0.001). The German parents experienced more negative feelings 
than the Dutch and Spanish parents in the same situation (mean score 3.0 (SD 0.8) 
compared to 3.5 (SD 0.7) and 3.7 (SD 1.0) respectively, p<0.001). Stressful feelings of the 
parents at the time of completing the questionnaire were similar, irrespective of the 
HLA-typing result, (both groups mean score 3.2; SD 0.7 favourable and 0.5 unfavourable 
result), but in Spain, parents receiving unfavourable results reported more stress than 
parents in the Netherlands and Germany (mean 2.8 (SD 0.6) vs. 3.4 (SD 0.5) and 3.1 (SD 
0.5) respectively, p<0.001).








HLA-DQ2 an/or DQ8 positive children
HLA-DQ2 an DQ8 negative children
54321
Very low chance Very high chance
 HLA-DQ2 and DQ8  
negative children
 HLA-DQ2 and/or DQ8  
positive children
What do you think of the chance for your 
child to develop coeliac disease?
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Consultation of a doctor in the month prior to filling in the questionnaire was reported 
equally among the DQ- (37%) and DQ+ (38%) children, with 8% reporting a frequent 
consultation in both groups. The majority of the parents of DQ- (63%) and DQ+ (65%) 
children found the frequency of illness in their child similar to the one in the general pop-
ulation. However, significantly more parents of DQ+ children (21%) had concerns about 
their children’s health compared to parents of DQ- children (10%) (p=0.022). When asked 
about specific health complaints of their children during the 3 months prior to filling in 
the questionnaire, these were similarly distributed among the DQ- and DQ+ children, 
with diarrhoea in 42% and 48% respectively, vomiting in 25% in both groups, abdominal 
distension in 19% and 26%, constipation in 23% and 30% and fatigue in 25% and 32% 
respectively. There were no significant differences between the countries regarding the 
perceived health of the children by their parents (data not shown).
Health Related Quality of Life (HRQoL)
This was analysed in 299 children aged 9 months to 6 years using TAPQOL. HRQoL was 
similar for all domains in the DQ- and DQ+ children with the exception of a lower score 
in DQ+ children with regard to the domain concerning problem behaviour.
Discussion
The results of this study, the first to assess the impact of HLA typing on families at 
risk for the development of CD, show a positive parental perception of HLA-typing in 
their children and that unfavourable results indicating risk for CD do not lead to a lower 
HRQoL in their offspring. It also demonstrates that despite good knowledge about HLA-
typing for CD, almost 50% of parents of a negative tested child think that this child has 
a chance to develop CD. These results are relevant, since over the years, HLA-typing 
has become more frequently used in the diagnostic process of CD and it is part of the 
European Society of Pediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) 
diagnostic guidelines on CD10.
The fact that half of the parents of children who tested negative misinterpreted the results 
of their child is remarkable, since the majority of these parents knew that their child could 
not participate in PreventCD due to no risk of CD. This pessimistic interpretation by the 
parents of a favourable result of genetic testing has been reported before after testing for 
cancer genes in children21. One explanation could be the failure of adjustment to the sud-
den removal of the disease scenario, as it has been found in genetic testing for Hunting-
ton disease22. The above mentioned misinterpretation of negative HLA findings opens the 
question whether parents correctly understand the results of HLA-typing for CD and of 
susceptibility genetic testing in general23. Paradoxical risk interpretation of genetic testing 
has also been reported in newborn screening for type 1 diabetes14, with 10% of mothers 
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over- or underestimating the risk. It is also known that processing statistical information 
is often difficult for people and that interpretation of results may be dependent on several 
factors, such as personal and cultural opinions24. This outcome should prompt physicians 
to make sure that parents understand the results and to improve the way of giving infor-
mation to the parents, for example with a short information brochure about genetic test-
ing. This could be helpful, especially since we found that parents who received favourable 
results were less inclined to look for additional information on HLA-genotyping and CD.
As expected, parents who received unfavourable HLA results experienced more negative 
feelings. On the other hand, regrets about HLA-typing were scarce and did not influence 
the parents’ willingness to repeat HLA-typing in future children. Our results show that 
HLA-typing results do not influence the HRQoL of children as perceived by their parents. 
However, although the overall concern about the health of their children was low, HLA 
positive results lead to more parental concerns in general, not being supported by more 
health care utilization or specific health complaints in the DQ+ group. One possible ex-
planation is that parents in our study are participating in a research project where they 
are frequently interviewed about the health of their children. Cultural differences with 
regard to genetic testing did not seem to be taking place, since similar results were seen 
in the different European countries. Data on parents of 46 children from Israel, who 
filled in the questionnaires on paper during visits to the hospital, are consistent with 
this finding. Our study has the strength of novelty and of having been done in a unique, 
international, prospective cohort of families with high risk of CD. Possible limitations of 
the study include that the validity of the tools used to assess the parental knowledge 
of and attitude towards HLA-typing has been not tested in other populations, since 
they were created for this study. Scale reliability, however, was tested and showed good 
scores. The question raises whether our group of parents, with a high educational level 
characteristic for people participating in research projects, is representative for CD fam-
ilies in general. On the other hand, if high educated parents misinterpreted HLA-typing 
results, it is likely that CD parents in general will do so even more. The vast majority of 
the participating parents were mothers, reflecting their role as being the primary care-
givers in most families. Given this fact, we cannot completely exclude that fathers may 
be less positive than mothers about HLA-typing in CD. Since the participating parents 
in this study were participants in the PreventCD project, one could argue that these 
parents are mostly people with a positive attitude towards screening for CD and HLA-
typing, and that our conclusions may not be supported by the parents of CD in general. 
However, the large size of the PreventCD cohort may be considered as representative for 
young children from families with high risk for CD15. Our study group also has a relatively 
small number of DQ- children, but this is characteristic for families with high risk for CD, 
as shown before9.
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Conclusion
Parents of CD families support HLA-typing for genetic risk determination for CD. Unfa-
vourable HLA results cause temporary negative feelings in the parents, but no increased 
health concerns about their children. The interpretation of HLA-DQ2 and/or HLA-DQ8 
negative results of their own children is difficult for the parents despite good knowledge 
of CD and HLA-typing in general. This should urge us to provide parents with good and 
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Towards an individual screening 
strategy for first degree relatives 
of coeliac patients











Coeliac disease (CD) is known to be more prevalent in first-degree relatives of patients. 
In this retrospective cohort study of 609 relatives between 1994 and 2016, we investi-
gated the effect of sex, HLA-type and age at time of index coeliac diagnosis. Pearson’s 
Chi-square test and Kaplan-Meier survival analysis were used as statistical analyses. 
CD screening was carried out for 427 relatives (70%), resulting in a prevalence of 15%. 
HLA-typing in 335 relatives showed HLA-DQ2/DQ8 positivity in 87.5%. In 63% of chil-
dren and all parents, coeliac disease was diagnosed at first screening. It was diagnosed 
significantly more often in females, HLA-DQ2 homozygosity, and children (all p<0.05). 
In children aged 0-1 year at time of index diagnosis, coeliac disease was diagnosed after 
consecutive screening in 58%, after 3.9 + 2.5 (max 10) years (p<0.001).
cOnclusIOn Future screening policies for relatives of coeliac patients should include 
retesting, especially in HLA-positive relatives younger than 10 years of age. In addition, 
one-time coeliac specific antibody testing alone could be sufficient to rule out the disease 




Coeliac disease (CD), which can develop at any age, is a chronic, immune-mediated 
disease in which alterations occur in the mucosa of the small intestine induced by inges-
tion of gluten in genetically predisposed individuals1. Gluten are storage proteins in wheat 
(gliadin), rye (secalin) and barley (hordein)2. The diagnosis of CD is made through detec-
tion of the presence of a variable combination of gluten-dependent clinical manifesta-
tions, CD specific antibodies, HLA-DQ2 and/or HLA-DQ8 haplotypes and enteropathy1. 
Serological testing for CD is possible through detection of IgA class transglutaminase 
type 2 antibodies (TG2A), endomysium antibodies (EMA) or antibodies against deami-
dated gliadin peptides1,3. CD can be successfully treated with a life-long gluten-free diet, 
which restores small bowel histology and clinical complaints in most cases4. CD is found 
to occur in 1% of the general population5. It is often unrecognized, which can be partially 
explained by the variable clinical presentation, from diarrhea, weight loss and abdominal 
pain, to nonspecific signs and symptoms such as fatigue, osteoporosis, iron deficiency 
anaemia and no symptoms at all, referred to as silent CD1. Later in life, untreated CD can 
lead to an increased risk of osteoporosis and even cancer2,6.The disease is multifactorial, 
and one in which genetics plays an important role. In 90-95% of coeliac patients the 
HLA-DQ2 haplotype is identified, with HLA-DQ8 being present in most of the remaining 
patients. Both haplotypes occur in 30-40% of the general population, which indicates 
that these haplotypes are necessary, but not sufficient, for developing CD1. As already 
demonstrated in many studies, first-degree relatives (FDRs) of coeliac patients are at a 
higher risk of developing CD than the general population, with a prevalence of CD in FDRs 
varying from 2.6-11.9%7-16. Therefore, the Dutch and European CD guidelines recommend 
CD screening in individuals at risk of developing CD, such as FDRs1,3. In FDRs without 
the HLA-DQ2 and/or DQ8 haplotypes, the chance of developing CD is nil, so follow-up 
through further CD investigations can be omitted3. On the other hand, FDRs who carry 
the HLA-DQ2 and/or DQ8 haplotypes, have an increased risk of approximately 10% of 
developing CD16-18. Thus, since CD is a condition that can evolve at different stages in 
life, repeated serologic tests for CD can be necessary in HLA-DQ2 and/or DQ8 posi-
tive FDR’s15,19. Several studies have shown that the risk of developing CD among FDRs is 
influenced by multiple factors, such as age, sex, relationship with the index patient and 
HLA-genotype11,16,20,21. However, CD guidelines do not give guidance about the frequency 
of CD screening and duration of follow-up needed in HLA-DQ2 and/or DQ8 positive FDRs.
The aim of this study in FDRs is to investigate the effect of sex, HLA-type and age at 
time of CD diagnosis in the index coeliac patient, in order to establish a better screening 
protocol for these high risk individuals.
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Methods
Study design and participants
A historic cohort in the Rijnstate Hospital in Arnhem, the Netherlands, included mothers, 
fathers and siblings of all 174 consecutive pediatric CD patients (up to 18-years) from 
1994 until January 2016. After 2012, two CD-specialised gastroenterologists in our hos-
pital started to refer offspring to the pediatric gastroenterologist, therefor 24 children 
(10 female) of 16 adult biopsy proven CD patients were also included between 2012 and 
January 2016. All pediatric coeliac diagnoses were based on ESPGHAN diagnostic criteria 
and all patients were seen at least once by succeeding pediatric gastroenterologists with 
a special interest in CD1,22. In parents, CD diagnosis was based on a combination of posi-
tive CD specific serology and Marsh > 2 duodenal lesions. FDRs were identified using the 
electronic patient record system, where detailed descriptions of the family setting are 
registered. Cross-check was done by identifying individuals living at the same address as 
the coeliac patient in order not to overlook FDRs. The FDRs were categorized in groups 
according to their age at time of coeliac diagnosis in the index patient: group 1: 0-1 year, 
group 2: 2-5 years, group 3: 6-10 years, group 4: 11-24 years, group 5: >25 years. Groups 1-4 
represent the siblings and children of coeliac patients and group 5 represents the parents 
of the index coeliac children.
According to (inter)national guidelines, screening was offered to all FDRs. Follow-up of 
FDRs was also discussed. If parents wanted follow-up screening in their (other) HLA-
DQ2 and/or DQ8 positive children annual or biannual visits were planned with screening 
of at least EMA combined with TG2A in most cases. Standard follow-up was not advised 
to parents themselves.
Since we focussed on FDRs and their specific risk of developing CD, relationship to the 
CD index patient was recorded. Also dated CD-specific serology, HLA-typing results 
(when performed) and diagnostic duodenal biopsies were recorded. In FDRs the follow-
up duration until eventual CD diagnosis was defined as the time between diagnosis of 
the index patient and CD diagnosis in the FDR. Total follow-up duration was defined as 
the time between diagnosis of the index relative of a FDR and the time of analysis in 
February 2016. HLA-typing results were considered as unknown if no HLA results were 
found in the electronic patient record, as negative if negative for DQ2 and DQ8, and 
as positive if positive for DQ2 and/or DQ8. HLA-DQ2 and/or DQ8 positive results were 
categorized according to the risk of development of the disease11,16,18 into a high, inter-




Pearson’s Chi-square test, unpaired t-test, Mann-Whitney U test and Kaplan-Meier sur-
vival analysis were used where appropriate. For comparison, a log-rank test was used 
stratified according to sex, HLA risk group or age group. For each item, a difference was 
found significant if p < 0.05. The data was analyzed in version 21.0 of the IBM Statistical 
Package for the Social Sciences (SPSS).
Medical ethical consideration
The procedures followed were in accordance with the ethical standards of the Medical 
Research Involving Human Subjects Act and the principles of the declaration of Helsinki 
(59th General assembly, Seoul, October 2008) of the World Medical Association. Formal 
approval from the local feasibility committee of Rijnstate Hospital Arnhem was obtained.
Results
A total of 609 FDRs were identified, for which it was found 70% (n=427) had been 
screened for CD (205 parents, 181 siblings and 41 offspring). The reasons for not per-
forming screening in the other 182 FDRs were not known. The overall prevalence of CD 
in the screened subjects was 15% (64/427). In 30% of all cases, CD was diagnosed after 
the initial screening. The participant flow is shown in Figure 1.
Table 2 shows the characteristics of the 427 screened FDRs with regard to sex, relation-
ship to the index patient, age at time of diagnosis of CD in the index patient, HLA risk 
group and follow-up duration. Significantly more females were diagnosed with CD (61%, 
Table 1 HLA risk group classification
HLA risk group Haplotypes
High-risk DQ2DR3/DQ2DR3, DQ2DR3/DQ2DR7
Intermediate-risk DQ2DR3/DQ7DR5, DQ2DR7/DQ7DR5, DQ2DR3/DQ8DR4, DQ2DR3/other*, DQ2DR7/DQ2DR7, 
DQ2DR7/other
Low-risk DQ2DR7/DQ8DR4, DQ8DR4/DQ8DR4, DQ8DR4/DQ7DR5, DQ8DR4/other, DQ7DR5/DQ7DR5, 
DQ7DR5/other
* Other: refers to any HLA-DQ haplotype except DQ2DR3, DQ2DR7, DQ8DR4 or DQ7DR5.
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p=0.031), however this gender effect was observed only in sisters and not in mothers 
and daughters of CD index patients (Table 2). HLA-typing was performed in 332 FDRs 
and 12.7% of them were found to be HLA-Q2 and/or DQ8 negative and therefore not at 
risk for CD.
Among the 290 FDRs who were HLA-DQ2 and/or DQ8 positive, CD was diagnosed in 
29% of the children (34 siblings and 16 offspring) and 6% of parents (3 mothers and 
4 fathers), with a mean follow-up duration after CD diagnosis in the index patient of 
2.7 years (SD ± 3 years). In 18% of the siblings and offspring, diagnosis was established 
without duodenal biopsies according to the latest ESPGHAN criteria because there were 
symptoms suggestive of CD1. In all parents, CD was diagnosed based on duodenal biop-
sies except in one mother, who was both TG2A and HLA-DQ2 positive and had resolu-
tion of symptoms after starting a gluten-free diet.
Figure 1 Flow chart of participants (first-degree relatives of coeliac patients)
* Coeliac disease (CD) diagnosis in children based on ESPGHAN diagnostic criteria, CD diagnosis in parents based on 
combination of positive CD specific serology and Marsh 2-3 duodenal lesions.
609 first-degree relatives of 174 pediatric and 16 adult coeliac  
index cases
Overall prevalence of CD in screened subjects 15%
Anti-endomysial and/or anti-tissue transglutaminase




diagnosis* in 5 parents
Consecutive screening:




CD diagnosis* in 32 children and 7 parents
Consecutive screening:





As shown in Table 2, the intermediate-risk HLA genes (DQ2DR3 heterozygosity and 
DQ2DR7 homozygosity) were the most prevalent, both in FDRs who were diagnosed 
with CD and those who were not (52% and 47% respectively). In contrast, high-risk HLA 
genes (DQ2 homozygosity) were significantly more common in FDRs who were diag-
nosed with CD (28% versus 12% in the FDRs without CD, p=0.001). The Kaplan-Meier 
survival analysis according to HLA risk group in Figure 2 shows that FDRs with high risk 
HLA genes were diagnosed significantly earlier than those in the intermediate or low 
risk groups (p=0.011). In 90% of the high risk FDRs, CD was diagnosed within 4 years 
of the diagnosis of the coeliac index case (13 at first screening and 3 during follow-up) 
compared to 80% and 75% in the intermediate and low risk group respectively.
In the 95 FDRs in whom HLA-typing had not been performed (noticeably more parents 
than children: 59% vs 33% respectively), CD was diagnosed in 3 mothers and 2 fathers 
Table 2  Characteristics of the 427 first-degree relatives of celiac patients with screening of coeliac disease (CD).
Characteristic CD +  CD - HLA-DQ2 and/or DQ8 -
Number of subjects n = 64 n = 321 n = 42









Sex – Female, %, p=0.031













































Mean follow-up duration in years until CD









†  Mean follow-up duration until CD development or not = time between CD diagnosis in the index patient and CD 
diagnosis in the FDR and/or the time of the study (January 2016).
NA: Not applicable
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and in 2 siblings, all based on positive CD specific serology and Marsh 3 duodenal lesions. 
There were no differences with regard to sex and mean follow-up time to CD diagnosis 
between FDRs with and without performed HLA-typing (data not shown).














Table 3  Correlation between the age of the first-degree relative (FDR) at time of index coeliac diagnosis and 
the age of the FDR at own coeliac diagnosis.
Children Parents










CD diagnosis (n) 24 (27%) 12 (23%) 11 (24%) 4 (24%) 13 (7%)
CD diagnosis at first screening 
(represented as % of CD diagnoses)
42 90 72 100 100
Mean follow-up duration until CD 
diagnosis (Q1-Q3 Tukey Hinges)
3.9 (1.9-5.4) 2.8 (0.2-5.2) 2.6 (0.2-6.4) 0.6 (0-1.1) 1.5 (0.5-1.9)
Follow-up duration without CD 
diagnosis (Q1-Q3 Tukey Hinges)
9.4 (6.1-12.2) 10.1 (5.2-15.1) 6.5 (2.4-10.8) 7.4 (0.5-10.7) 9.9 (5.8-13.9)
Mann-Whitney U test with regard 
to follow-up duration, p-value
<0.001 <0.001 0.003 <0.001 <0.001
* SD= standard deviation
** Mean follow-up duration in years without CD diagnosis until analysis in February 2016
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Table 3 shows the significant association between the age of the FDR at time of co-
eliac diagnosis in the index patient and the identification of CD after the first screening 
(p<0.001), with young children being diagnosed after a longer follow-up period than older 
children and adults. Siblings and offspring were significantly more often diagnosed with 
CD when compared to parents of coeliac patients (25% and 7% respectively, p<0.001).
In total, CD was diagnosed at first screening in 63% of the children and in all the parents 
(Table 3). The youngest group (0-1 years) had the lowest CD identification rate at first 
screening (42%), while all CD cases were identified within 10 years of follow-up. All chil-
dren aged 2-5 years were diagnosed at first screening, except for one sister, aged 2.2 years 
at the time of CD index diagnosis, who was diagnosed at the age of 7.1 years (Table 3). 
In children aged 6-10 years, only 2 siblings were not diagnosed during the first screening 
(sister of 6.7 years and brother of 6.8 years of age at the time of index diagnosis, diagnosed 
during follow-up at 12 and 14.8 years respectively). Both siblings had complaints sugges-
tive of CD, being the reason for the renewed follow-up screening. All other coeliac children 
in this age group were identified during first screening. In the adolescent group (11-24 
years) all coeliac cases were identified during first screening. In the majority of parents 
(61%), first CD screening was done within 1 year after diagnosis in the index patient, in 
3 parents (23%) after 1-2 years and in 2 parents (15%) after 4.0-5.6 years.
Discussion
This retrospective cohort study in families of coeliac patients substantiates the higher 
prevalence of CD found in FDRs, which in our study was 15% after screening. Our data show 
a higher rate of CD in siblings and offspring when compared to parents of CD patients, as 
demonstrated by previous studies and a recent meta-analysis8,21,23. Again, as previously 
demonstrated, we found a higher prevalence of CD in sisters of CD patients21. In agreement 
with the results of prospective studies in birth cohorts of FDRs, we have found a signifi-
cantly higher prevalence, at a younger age, in children who are HLA-DQ2 homozygous11,24.
Our results suggest that the timing of CD specific antibody testing could be individualized 
depending on the relationship of the FDR with the index patient and her/his age at time of 
the index diagnosis. Since all CD cases in adolescents and parents were detected during 
first screening, further follow-up screening might not be necessary in this age category. 
Although there were 2 parents with a longer interval between the coeliac diagnosis in the 
index patient and their own diagnosis, diagnoses in these cases were still the result of the 
first screening. The reason for this delay could not be retrieved from the patient records, 
but might be due to the fact that screening was left to the discretion of the parents.
75
CoeliaC sCreening in first degree relatives
Our findings with regard to CD diagnosis in parents of coeliac patients are in accordance 
with a Swedish cohort of FDRs who were retested 20-25 years after first CD screening 
because of newly diagnosed CD in the family25. Only 2 new cases of CD were found, with 
one of these FRDs already having mild enteropathy 20-25 years earlier. On the other 
hand, our findings support the fact that repeated screening is necessary in offspring of 
CD patients and siblings younger than 10 years of age in order to be able to diagnose CD. 
Due to the retrospective nature of our study we can only indicate that repeated screen-
ing for CD beyond the age of 10-12 may not be necessary. All children in our cohort who 
were diagnosed during adolescence, were either adolescents at the time of first screen-
ing or had a long period between the first and follow-up screening.
The strength of our study lies in the fact that we have studied a large group of FDRs. 
The percentage of CD found in our cohort (15%) was similar to the percentages found in 
other studies11,21,26 so the results appear representative of coeliac FDRs in general. This 
Figure 3 Screening algorithm for family members of (newly) diagnosed coeliac patients
* Consider HLA-typing and referral to gastroenterologist in case of negative CD specific antibodies but signs 
suggestive for coeliac disease: consider gluten challenge and reinvestigation.
** During adolescence: repeat CD specific serology in case of future signs suggestive for coeliac disease




>10 years of age
CD specific serology





Negative: repeat every 
year until
adolescence**
Negative: no further 
screening unless signs 
suggestive for CD*
Negative: repeat  




Positive: refer to 
pediatric
gastro-enterologist
Positive: refer to  
gastro-enterologist







is supported by the distribution of HLA-types found in our cohort which is similar to 
other cohorts described in the literature11,16,24, even though the percentage of HLA-DQ2/
DQ8 negative FDRs in our study (12.5%) was somewhat lower than described before 
(14-21%)11,27,28.
One possible limitation is the retrospective cohort study design. After initial screening of 
CD, which was done in 70% of FDRs, CD specific antibodies were not tested on a regular 
basis, since it was left to the FDRs/parents whether follow-up took place23. A stringent 
repetitive screening policy in FDRs might have led to an even higher prevalence of CD than 
found in our study, therefore stressing further the importance of follow-up. Prospective 
studies with regular screening of FDRs are needed to be able to develop a tailored and 
effective screening strategy for CD in FDRs. In the meantime, we propose an algorithm 
that can be used, preferably within the first months after coeliac diagnosis (Figure 3).
Since family members tend to have a lower gluten containing diet when compared to 
the general population, one has to bear in mind that negative serology in HLA-DQ2 and/
or DQ8 positive FDRs can lead to unjust reassurance. In those cases, gluten challenge 
with repeated serology and duodenal biopsies are justified.
Conclusion
Screening of FDRs of coeliac patients in a clinical setting revealed a prevalence of CD of 
15%. Repeated testing of CD specific serology in HLA-DQ2 and/or DQ8 positive siblings 
and offspring, younger than 10 years of age at the moment of CD diagnosis in the index 
patient, is necessary to diagnose CD as early as possible. This should be continued until 
at least early adolescence (10-12 years of age) and is especially true in HLA-DQ2 homo-
zygous siblings of coeliac patients. In addition, one-time CD specific antibody testing 
could be sufficient to diagnose CD in siblings who are adolescents at the time of diag-
nosis in the index patient, and parents of newly diagnosed coeliac children. Our results 
may contribute to developing future recommendations for CD screening frequency and 
follow-up duration of relatives of coeliac patients.
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Raising the cut-off level of anti-tissue 
transglutaminase antibodies to detect 
coeliac disease reduces the number of 
small bowel biopsies in children with 





















ObjectIve Our aim was to study the optimal cut-off value for the anti-tissue trans-
glutaminase type 2 IgA antibody in serum (TG2A) to select for diagnostic small bowel 
biopsies for coeliac disease (CD) in children with type 1 diabetes mellitus (T1DM). In par-
ticular, we endeavour an increase in specificity and positive predictive value and more 
importantly a decrease in normal histology, without losing too much sensitivity.
PatIents and MethOds Children with T1DM who had both elevated TG2A titers dur-
ing regular screening and duodenal biopsies during the course of their diabetes were 
included. Anti-endomysial antibodies (EMA) if present were recorded. The optimal TG2A 
cut-off value was determined using receiver operating characteristics (ROC) curve analy-
sis; and compared with the cut-off value used in the ESPGHAN guidelines in terms of 
sensitivity, specificity, positive and negative predictive value. TG2A titers were expressed 
as the ratio between the value obtained and the upper limit of normal (ULN).
results A total of 63 children were included. The optimal cut-off value for perform-
ing a biopsy proved 11xULN. Raising the cut-off value from 3xULN to 11xULN changed 
the sensitivity from 96% to 87%, increased the specificity from 36% to 73%, the posi-
tive predictive value from 88% to 94% and the negative predictive value from 67% to 
53%. The percentage of normal histology was reduced from 12% to 6%.
cOnclusIOn Our data indicate that increasing the TG2A cut-off value for perform-
ing duodenal biopsies in children with T1DM and suspected CD leads to a substantial 
reduction of unnecessary biopsies. We advocate to adapt the ESPGHAN 2012 guidelines 





Children with type 1 diabetes mellitus (T1DM) are at risk of developing coeliac disease 
(CD). Both conditions are autoimmune diseases showing strong linkage to the human 
leukocyte antigen (HLA) system1. The prevalence of CD among patients with T1DM is 
estimated between 3 to 10%2. Most children with both T1DM and CD are asymptomatic 
or present with non-specific symptoms3. Duodenal biopsies is the gold standard for diag-
nosis of CD in children with T1DM3. CD is not only believed to cause diminished diabetes 
control in children with T1DM, but may also result in complications, including decreased 
bone density and gastrointestinal malignancies1. CD is treated with a gluten-free diet 
(GFD)4. Therefore, children with diabetes are regularly screened for CD; at diagnosis of 
T1DM and subsequently every 1-2 years thereafter5. Anti-tissue transglutaminase type 2 
IgA antibodies (TG2A) are commonly used for screening and have a sensitivity and speci-
ficity above 90%6. Despite this high accuracy, the interpretation of the TG2A titers in 
children with T1DM has proven difficult. Significant quantitative differences exist among 
different TG2A assays7, elevated TG2A titers often show spontaneous normalization in 
children with T1DM8 and people at genetic risk for CD (like children with T1DM) have more 
often false-positive TG2A results9. In 2012, the European Society for Pediatric Gastroen-
terology, Hepatology and Nutrition (ESPGHAN) introduced new guidelines for diagnosing 
CD10, including an algorithm for asymptomatic children belonging to a high-risk group, 
like children with T1DM. In this algorithm, the cut-off value of serum TG2A titers for 
performing biopsies in these children is 3x upper limit of normal (ULN). This study was 
prompted by our observation that biopsies performed in children with T1DM and TG2A 
titers >3xULN are often not consistent with CD. We hypothesize that the cut-off value of 
3xULN was chosen too low. The aim of our study was to investigate the optimal cut-off 
value for the TG2A titers in order to overcome negative biopsies in children with T1DM 
without losing too much sensitivity.
Patients and methods
Study design and settings
This is a retrospective observational study covering the time period 2002-2015. Data 
were collected both at University Hospitals and middle to large secondary care clinics: 
Leiden University Medical Center (LUMC) Leiden, University Medical Center Groningen 
(UMCG), Rijnstate Hospital Arnhem, Haga Hospital The Hague, Children’s Diabetes Cen-
tre Nijmegen (CDCN), Maas Hospital Pantein Beugen, Spaarne Hospital Hoofddorp, St. 
Antonius Hospital Nieuwegein, Zuwe Hofpoort Woerden, MC Zuiderzee Lelystad, Isala 
Hospital Zwolle, Deventer Hospital and University Medical Center Utrecht (UMCU). Due 
to the retrospective nature of this study, informed consent was not required. The pro-
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cedures followed were in accordance with the ethical standards of the Medical Research 
Involving Human Subjects Act and the principles of the declaration of Helsinki (59th 
General assembly, Seoul, October 2008) of the World Medical Association. Formal ap-
proval from the local feasibility committee of Rijnstate Hospital Arnhem was obtained. 
Study group
The study population consisted of all consecutive children and adolescents (<19 years of 
age) with T1DM, who underwent esophagogastroduodenoscopy with duodenal biopsies 
because of elevated TG2A titers>3xULN10. Screening with CD specific serology in these 
children was done every 1-2 years after diagnosis of T1DM according to the ISPAD in-
ternational guideline for the management of pediatric T1DM, regardless of symptoms5. 
Exclusion criteria were: IgA deficiency, a GFD at the time of duodenal biopsies, CD diag-
nosed before T1DM and an interval >180 days between measurement of the TG2A titer 
and duodenal biopsies.
Data collection
Data was retrieved from either patient charts or electronic data systems and entered into 
standard forms using Research Manager version 5.2.0.5 (Cloud9 Health Solutions,the 
Netherlands). Clinical, anthropometric and laboratory data were collected. This included 
several baseline characteristics such as age at first duodenal biopsies, gender, other 
autoimmune disease(s), family history of CD and other autoimmune diseases and GFD 
adherence. Presence of symptoms suggestive for CD10 was also registered: chronic or 
intermittent diarrhea11, failure to thrive, weight loss, delayed puberty, amenorrhoea, 
iron-deficiency anaemia, chronic abdominal pain, chronic constipation, chronic fatigue, 
dermatitis herpetiformis-like rash and spontaneous fracture/osteopenia.
Serology
Since 13 different hospitals participated in this study, TG2A titers were assessed while 
using different types of assays, different arbitrary units and different cut-off values. In 
order to compare the TG2A titers, results were expressed as the ratio between the value 
obtained and the upper limit of normal. This ratio was rounded to whole numbers. 
When a TG2A level was written in the file as >50, it was regarded as 50 and >128 was 
regarded as 128, etcetera. Since some patients were analyzed twice (accompanied by a 
second biopsy), without starting a GFD in between, the total number of measurements 
exceeds the total number of patients included in our study. TG2A IgA ELISA’s used were 
obtained from 6 different manufacturers: Aesku (Wendelsheim, Germany), n=4; Euroim-
mun (Lübeck, Germany), n=2; Inova (San Diego, California), n=4; Orgentec (Mainz, Ger-
many), n=3; Phadia (Freiburg, Germany) n=50; Sanquin (Amsterdam, The Netherlands), 
n=2. Anti-endomysial antibodies (EMA) as determined by indirect immunofluorescence 




All children included in this study underwent esophagogastroduodenoscopy in order to 
obtain duodenal biopsies, 4 from duodenum and 1-2 from bulb. Histological findings 
were revised and classified according to the Marsh criteria12 by a single pathologist, 
specialized in Marsh typing. This pathologist was blinded for previous interpretations 
and clinical and laboratory findings. Definite CD was confirmed by Marsh 2 or 3 histol-
ogy in combination with the already known positive coeliac serology. CD autoimmunity 
without histology alterations in the small bowel biopsies was considered potential CD10.
Statistical analysis
Continuous data are presented as mean ± standard deviation (SD). Differences in means 
between groups were tested using the Students’ T-test. Categorical data are presented as 
frequencies and percentages. Differences in percentages between groups were tested using 
the Pearson chi-square test or Fisher’s Exact test. Receiver Operating Characteristic (ROC) 
analyses were performed to determine the optimal TG2A cut-off value. Sensitivity, specific-
ity, positive and negative predictive values were calculated. Sensitivity and specificity were 
tested by the McNemar test. Statistical analysis was performed using IBM SPSS Statistics 
(version 18.0). A P-value less than 0.05 was considered to indicate statistical significance.
Results
Study design
In our study, 77 children were eligible. A total of 63 children fulfilled our inclusion crite-
ria. 14 children were excluded (Figure 1). The median interval between TG2A measure-
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ment and duodenal biopsies was 72 days (range 0-178). The total number of analysed 
TG2A titers was 65, since 2 patients underwent a second paired antibody determination 
as well as second biopsies.
Baseline characteristics
The baseline characteristics of all patients are presented in Table 1. In our study popu-
lation, a preference for females was noticed (62%). Symptoms suggestive for CD were 
present in 37% of the patients. When comparing asymptomatic with symptomatic chil-
dren, no statistically significant differences were observed in baseline characteristics, 
neither in associated autoimmune disease, family history of associated autoimmune 
disease, family history of CD nor in Marsh histology. Three children suffered from auto-
immune hypothyroidism. The prevalence of CD in the total group is 83%, with a higher 
prevalence in the asymptomatic patients when compared to the symptomatic children, 
88% and 74% respectively (p>0.05).
Analysis of cut-off value
ROC-curve analysis showed that the optimal TG2A cut-off value for performing a biopsy 
in children with T1DM, as calculated by ROC-curve analysis, is 11xULN. This cut-off value 
provides a sensitivity of 87% and a specificity of 73%. The cut-off value of 3xULN, de-
scribed and advised in the latest ESPGHAN guideline, results in our study in a sensitivity 
of 96% and a specificity of 36%. Figure 2 shows the ROC-curve, Table 2 shows the 
coordinates of the curve, with sensitivity and 1-specificity.
Table 1  The baseline characteristics and differences between the asymptomatic and symptomatic children 










Mean age in years (at time of 1st biopsy) 9.7 (SD 4.7) 10.5 (SD 4.2) 8.2 (SD 5.1) 0.06
Female n(%) 39 (62) 27 (68) 12 (52) 0.23
Other autoimmune disease n(%) 3 (5) 3 (8) 0 (0) 0.31
Family history of other autoimmune 
disease n(%)
21 (33) 13 (33) 8 (35) 0.85
Family history of coeliac disease n(%) 4 (6) 2 (5) 2 (9) 0.62
CD (Marsh 2-3) n(%) 52 (83) 35 (88) 17 (74) 0.31
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Changing the cut-off value of TG2A: consequences for clinical practice
Table 3 illustrates the different positive predictive values (PPV) for small bowel muco-
sal atrophy, depending on different cut-off values for normality (CoN), from 3xULN to 
11xULN.
Table 2  Coordinates of the receiver operating characteristics curve to determine the optimal tissue 
transglutaminase antibodies cut-off value for performing duodenal biopsies.











Figure 2  Receiver operating characteristics curve to determine the optimal tissue transglutaminase antibodies 
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PPV for CoN increases from a minimal of 89% at 3xULN to a maximum of 94% at 11xULN 
with NPV of 67% and 53% respectively. Raising the CoN from 3xULN to 11xULN results 
in a decrease in sensitivity from 96 to 87% (p=0.06) and an substantial increase in 
specificity from 36 to 73% (p=0.13). Overall, a CoN of respectively 3 and 11xULN resulted 
in 12% (7/59) and 6% (3/50) normal (false positive) duodenal biopsies.
EMA as additional test
EMA was negative in only 3 cases, who all had Marsh 0-1 histology. Adding EMA positive 
results did not improve the PPV of increased TG2A levels for villous atrophy, since 50% 
of EMA positive patients had normal duodenal histology.
Discussion
With this study in T1DM children, we have shown that it is justified to increase the speci-
ficity and PPV by increasing the current TG2A cut-off value for performing diagnostic 
biopsies for CD. In order to have the highest NPV, we believe it is best raised to 11xULN 
and not to 10xULN even though the latter is commonplace for pediatricians vice versa 
not to perform duodenal biopsies in symptomatic children. Our data underline the fact 
that the choice of the cut-off of >3xULN for performing diagnostic biopsies in children 
with T1DM detected by screening, as part of the diagnostic algorithm for asymptomatic 
risk groups in the 2012 ESPGHAN guidelines for CD10, was not based on evidence, but on 
Table 3  Diagnostic performance of different cut-off values of normality of tissue transglutaminase antibodies











value for CD  
(95% CI interval)
Negative predictive 
value for CD  
(95% CI interval)
>1.0 65 54 100 18 85.7 (82-89) 100
>3.0 59 52 96 36 88.7 (83-92) 66.7 (29-91)
>5.0 55 50 93 55 90.9 (84-95) 60 (34-82)
>10.0 51 47 87 64 92.2 (84-96) 50 (31-70)
>11.0 50 47 87 73 94.0 (86-98) 53.3 (34-71)
>13.0 49 46 85 73 93.9 (85-98) 50 (32-68)
>15.0 38 35 65 73 92.1 (81-97) 29.6 (20-41)
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consensus aiming to avoid unnecessary biopsies. We decided not to exclude the symp-
tomatic children, who were also found in our study population, since the TG2A screening 
was done during regular, planned visits rather than due to symptoms. In our cohort, 55% 
of the children with Marsh 0-1 histology were also “symptomatic”, which may reflect 
the fact that the symptoms are non-specific for CD. Our results are in line with those of 
several recent studies in children with T1DM showing that TG2A levels varying from 5-8 
to 10xULN were stronger predictive of villous atrophy than >3xULN7,8,13,14. While screen-
ing tests usually optimize sensitivity to find new patients15, specificity is the parameter 
that needs optimization to avoid false-positive results. The latter is in our opinion crucial 
in T1DM children suspected of CD. First because endoscopy is an important burden for 
children who already have a chronic disease and omitting biopsies means avoiding the 
risks of anaesthesia in these children. Second, unnecessary biopsies should be prevented 
from a cost-effective point of view15.
In our opinion, the decrease in sensitivity by increasing the CoN of TTGA to >11xULN 
is acceptable, since normalization of elevated TG2A can occur in up to a third of the 
asymptomatic T1DM patients on a gluten containing diet16, allowing clinicians to wait 
and see first in these patients. In this recent retrospective study in Israel of newly diag-
nosed children with T1DM, high TG2A levels (>10x ULN) at diagnosis and three months 
thereafter, were predictive of CD16. Furthermore, if normalization does not occur and 
CD diagnosis is established with duodenal biopsies after all, this does not seem to have 
short term adverse effect either on diabetes regulation or on bone mineral density17,18. In 
our cohort, EMA did not contribute to the question whether or not to perform diagnostic 
biopsies. EMA negativity seemed to point to normal histology, but we were not able to 
draw a definite conclusion due to the small number of EMA negative patients, so future 
(prospective) studies are needed to sort this out.
Since children with T1DM with positive CD serology but normal duodenal histology can 
be considered potential CD patients, regular monitoring of CD serology is warranted. 
Recommendations on treatment and frequency of follow-up in potential CD are lacking, 
but since development of active CD is described in a third of the patients on a gluten con-
taining diet19, follow-up is important. In patients with T1DM and potential CD, young age 
and persistent positive TG2A over time seem to increase the risk of transfer into active 
CD16. In our cohort, we also found a tendency towards younger age in the group that was 
diagnosed with CD (p=0.06). Our result indicate that withholding biopsies is acceptable in 
children with T1DM and low TG2A titers if serology is being followed over time. Other stud-
ies, that show spontaneous normalisation8,20 or fluctuation13,17 of CD specific antibodies 
support our finding that low TG2A titers should be followed over time without performing 
immediate duodenal biopsies. Since children with T1DM need medical checks on a regular 
basis, assessment of TG2A every 6-12 months is in our opinion feasible. Performing CD 
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specific serology only in symptomatic children is not advised, since we have found an even 
higher prevalence of CD in asymptomatic patients when compared to symptomatic chil-
dren, 88% and 74% respectively. Other studies report varying results. In one study, 71% of 
children with both T1DM and CD reported no gastrointestinal symptoms21, while in anoth-
er study, 76% of children with both conditions had at least 1 gastrointestinal symptom22.
One of the strengths of our study is that this is the first to perform ROC-curve analysis 
to determine the TG2A cut-off value for performing biopsies in children with T1DM. Fur-
thermore, biopsies were revised by a single pathologist specialized in Marsh typing. For 
this reason, histological examination was not affected by interobserver variability23. In 
addition, this is as far as we know, the first and largest study in type 1 diabetic children 
revising the performance of the revised ESPGHAN diagnostic criteria for CD10.
The limitations of our study relate to its retrospective character and the sample size. 
Furthermore, we have compared TG2A measured with different types of assays. In the 
absence of an international standard, expressing the outcome in multiples of the ULN is 
currently the best option which has been used in several studies. Hopefully, in the near 
future an international standard will be introduced. It has been stated that comparison 
based on multiples of the ULN are valid24, because studies have shown acceptable agree-
ment between most second-generation kits25,26. Several other studies26,27 have used 
multiples of ULN to compare data from different manufacturers. ROC-curve analysis in 
which only data from Phadia, Aesku and Euroimmun (chosen because they showed good 
agreement in xULN in Table A from the ESPGHAN guidelines10) were included, resulted in 
the same ROC-curve (data not shown).
In conclusion, we have shown that raising the current cut-off level of TG2A to 11xULN 
in children with T1DM to perform duodenal biopsies results in a 50% decrease of false 
positive and thus unnecessary biopsies. In diabetic children with TG2A levels lower than 
11xULN, no diagnostic biopsies should be performed, but serological follow-up on a 
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Although coeliac disease (CD) is a frequent, but still underdiagnosed disease, focus in 
research should not only be on diagnostics and novel therapies, but also on best ways to 
take care of and monitor patients once they are on a gluten-free diet (GFD). In addition, 
evidence based screening policies in populations at risk in order to diagnose CD as early 
as possible should be developed as secondary prevention of the disease. The questions 
formulated at the start of this thesis with regard to these 2 domains are presented in 
Table 1, together with the assembled recommendations.
In-depth discussion of the findings and recommendations
Until present, the GFD is the only treatment of CD. Although it has a proven positive 
effect on the health of the coeliac patient, effective long-term management programs 
are lacking for children as well as for adults. The need for effective long-term follow-up 
to improve compliance with the diet and outcome of coeliac patients has been recog-
nized by many expert groups1–5, since delay of the GFD appears to lead to an increased 
risk of co-morbidity, mortality and tendency to a lower quality of life6,7. Therefore, in 
Table 1  Main conclusions of this thesis
Questions Findings Recommendations 
Do nutritional deficiencies persist or 
develop in coeliac children after start 
of a GFD?
Nutritional deficiencies recover 
within 1 year of GFD.
Standard blood-investigations 
besides CD specific serology are not 
necessary after one year of follow-up.
Do short GFD questionnaires detect 
infrequent dietary transgressions in 
coeliac children?
The short dietary questionnaire 
developed by Biagi does not provide 
more information than CD-specific 
serology. 
The standardized dietary interview, 
especially if completed before a 
face-to-face consultation, provides 
detailed information on dietary (non-)
compliance. 
What is the impact of HLA-screening 
in children at risk for coeliac 
development?
Parents of young children from 
coeliac families support HLA-typing 
and would repeat it in future children.
HLA-typing should be offered to 
children from risk families with the 
associated information provided.
What is the best screening method 
in FDRs of newly diagnosed coeliac 
patients?
One time screening could be enough 
in adolescent siblings and parents of 
newly diagnosed coeliac patients.
Regular screening by means of CD-
specific serology should be offered 
to all HLA-DQ2 and/or DQ8 positive 
pediatric FDRs <10 years of age. 
When should duodenal biopsies 
be performed in children with 
T1DM and elevated TG2A serology, 
since serology is often found to 
be false positive and/or declining 
spontaneously in these children?
In asymptomatic children with 
T1DM, 12% of the children have 
normal duodenal mucosa when 
biopsied in case of a TG2A titer of 
>3xULN. 
Follow-up of serology instead of 
performing endoscopy to retrieve 




2016, evidence-informed expert recommendations were published for the management 
of CD in children by pediatric gastroenterologists from the United States of America8, in 
which the shortage of good quality data regarding this matter was emphasized. At pres-
ent, standard medical care for CD children consists of regular visits to the pediatrician or 
pediatric gastroenterologist to evaluate overall health, anthropometrics, GFD adherence 
and laboratory investigations including CD specific antibodies and additional tests to 
rule out deficiencies and co-morbidity. With this in mind, it is important to acknowledge 
earlier reports that have indicated that follow-up care is not being provided to all pa-
tients, both in the pediatric as adult population9–12. In a pediatric cohort in Israel, it 
was shown that patients lost to follow-up have a poorly controlled disease with more 
non-adherence to the diet and positive CD-specific serology13. One can only speculate 
whether this non-compliance leads to more long-term complications, since follow-up 
data are lacking, both in adults as well as in children, and in untreated as well as treated 
patients. It is therefore indeed relevant for the establishment of evidence based follow-
up care of CD patients treated with a GFD.
This was the reason to study eventual nutritional deficiencies that may occur in CD pa-
tients and that are usually checked during follow-up. These alterations, although often 
present at diagnosis, disappear within one year of GFD, as we have shown in Chapter 2. 
This means that standard blood-investigations besides CD specific serology are not nec-
essary after one year of follow-up. This outcome is important, due to its consequences 
for the organization of the health care for children with CD, because blood tests are 
time-consuming and expensive, and in a few children also painful and frightening. The 
percentages of nutritional deficiencies found in our study were comparable with previ-
ous studies, with the exception of vitamin B12, which was much lower in our cohort 
(2%) in comparison to earlier studies in adolescents and adults (12-41%)14-17. Our findings 
on the frequency of thyroid dysfunction (nearly 4%) are similar to the ones from previ-
ous studies, with the prevalence of thyroid autoimmunity (elevated thyroid stimulating 
hormone (TSH) or presence of thyroperoxidase (TPO) antibodies), hypothyroidism and 
hyperthyroidism varying from 10-26%, 2-6% and 1%, respectively18,19. The rationale be-
hind thyroid function testing as part of a CD patient’s follow up is based on the high 
frequency of thyroid autoimmunity in CD20, but there is conflicting evidence about the 
GFD’s protective effect in the development of auto-immune thyroid disease21–23. Based 
on our results, routine testing of TSH, commonly used to screen for thyroid disease, 
should be discouraged, since (temporarily) abnormal results occur often without ab-
normal FT4 levels and thyroid disease. This can lead to overdiagnosis and anxiety in 
patients and parents. Thyroid testing should therefore be reserved for symptomatic 
children, presenting with abnormal growth or pubertal development, fatigue, altered 
defecation and appetite, muscle aches or tremor, ophthalmopathy, thermodysregula-
tion and altered school performance. If tested, FT4 levels should be determined. Since 
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mucosal healing after start of a GFD tends to behave similarly in adults and children, we 
hypothesize that the same advice could be given to coeliac adults, but there is no cur-
rent evidence to support this.
The next step enabling us to evaluate the management and follow-up of children with 
CD is defining the best way to assess dietary adherence, which is the only available treat-
ment. Since the diet is not always easy to follow, identifying the patients who do and do 
not comply to the diet is vital. While an extensive dietary evaluation by a trained dietitian 
is considered the best method to evaluate GDF adherence, this method is time-consum-
ing, taking 20-30 minutes per patient, and requires expert personnel. In Chapter 3, we 
have shown that a standardized dietary questionnaire is a good alternative to the face-
to-face contact with a dietitian. A short questionnaire developed and tested in adults24, 
did not provide more information on diet adherence than anti-tissue transglutaminase 
type 2 antibodies (TG2A). Both do not detect all errors in children and adolescents with 
CD. We have pointed out a decreased dietary compliance in adolescents, an established 
fact in CD populations25–27. Sex, age at CD diagnosis and the presence of other family 
members with CD did not influence compliance, nor did being on another diet besides 
the GFD or the presence of complaints after gluten ingestion. Despite our efforts, we 
were unable to reduce the length of the dietary interview. However, with the increasing 
use of electronic patient records and eHealth tools, completing questionnaires before or 
during a medical consultation should be easily implemented in the health care for chil-
dren and young adults with CD. The routine use of this dietary questionnaire especially 
when completed before the face-to-face contact, in combination with TG2A determina-
tion, will facilitate the communication between patients/parents and doctors, with a 
better focus on pitfalls and problems with the GFD. It will help the doctor to have an 
insight into possible dietary transgressions and reasons why and when they occur. This 
will provide the opportunity to anticipate on possible educational counselling and sup-
port. We expect that this will contribute to improvement of care for CD patients by, on 
the short term, empowering them leading to a better diet adherence, and possibly on 
the long-term, by avoiding complications of their disease. Not only will it be a useful tool 
in daily practice, but the dietary interview can also be used in prospective studies look-
ing at long-term outcome of CD patients on a GFD. Novel methods of measuring gluten 
immunogenic peptides (GIP) in urine and in faeces can add value to diet monitoring28,29. 
GIP enables direct and quantitative assessment of gluten intake. It can help to detect in-
cidental dietary transgressions that are not detected by CD specific serology and to iden-
tify patients non-compliant with the diet. However, because GIP analysis only detects 
gluten ingested a few days prior to testing, gluten ingestion before this time may remain 
undetected. GIP determinations might also be helpful in patients who adhere to the diet, 
but who have persistent elevated TG2A. If TG2A is still declining and GIP is negative on 
repetitive basis, reassurance of patients and their parents is probably justified.
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Another step forward to improve health and quality of life in coeliac patients is to dimin-
ish the level of under diagnosis. To be able to do so, awareness of the disease and an 
increased level of suspicion, both among doctors and the general public, is important. 
In addition, secondary prevention by early diagnosis and treatment should be further 
improved by developing screening programs for risk groups. When addressing screening 
for CD, it is important to look at the benefits of the outcome first of all. Looking at the 
literature, there is some evidence for screening strategies as a method of preventing 
complications and reducing medical costs30–32. However, benefits and cost-effectiveness 
of screening remain controversial33,34. Active case finding can be considered, albeit 
well known that the use of symptoms to identify CD patients has its limits. As it hap-
pens symptoms associated with CD are as prevalent in individuals with and without 
the disease35. However, case finding programs in children based on symptoms are an 
alternative for general screening programs, which is opposed to by the Medical Ethical 
Committees in the Netherlands. Since health benefits after diagnosis and treatment are 
expected in symptomatic children, permission to perform the GLUTENSCREEN study in 
the youth health care in the province North-Holland in the Netherlands was granted. 
Screening for CD in certain high risk groups is recommended both by the Dutch and 
European CD guidelines2,36, as individuals with other autoimmune diseases such as type 
1 diabetes mellitus (T1DM), autoimmune thyroid and liver disease, individuals with syn-
dromes like Down, Turner and Williams syndrome and with selective IgA deficiency and 
also first degree relatives (FDRs) of coeliac patients have a higher risk of getting the 
disease. In order to achieve better care for high risk groups, involvement of general 
practitioners in the Netherlands is imperative when updating coeliac guidelines, since 
their own current guideline on CD does not advice to screen FDRs37, who mostly are 
under medical attention of the general practitioner.
Because of the high negative predictive value of HLA-typing for CD, unnecessary inves-
tigations in HLA-DQ2 and DQ8 negative individuals can be avoided. This given forms the 
basis for the advice in the ESPGHAN CD Guidelines to use HLA-typing as the first step 
of screening in risk-groups2. However, in FDRs the percentage of HLA-Q2/DQ8 negative 
individuals is low, in the cohorts we have studied for this thesis 12.5% (Chapter 4) and 
15% (Chapter 5), quite comparable to what was found in other cohorts38,39. The same 
applies for diabetic patients, in whom several studies have demonstrated that absence 
of HLA-DQ2 and/or DQ8 haplotypes is scarce40–42. Together with the fact that HLA-
typing is at present quite expensive and the difficulty for people to interpret the results, 
should prompt us to question this advice. On the other hand, in this day and age of 
shared decision making, it is not only up to the doctor to decide whether this absolute 
risk is something to know or not. We have demonstrated that parents of young children 
from coeliac families support HLA-typing and would repeat it in future children (Chap-
ter 4). They would even be prepared to pay for the screening of their offspring43. In order 
to judge whether parents can actually be involved in such decisions, it is important not 
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only to know their opinion but also whether they are able to understand the background 
of genetics, which is notorious for its complexity and related cognitions. Despite the 
good knowledge that parents in coeliac families have with regard to HLA-typing on its 
own, misinterpretation of HLA negative results occurred in 48% of cases (Chapter 4). 
Parents who knew that presence of HLA-DQ2/DQ8 was necessary for individuals to be 
able to develop CD, thought that there was still a chance for their HLA-DQ2/DQ8 nega-
tive child to become a coeliac. Possibly, it is hard for them to adjust to a favourable out-
come if the disease scenario disappears. It should however prompt physicians to make 
sure that parents understand the results and to improve the way of giving information. 
The information brochure that has been developed for this purpose in Dutch is attached 
as Supplemental material appendix D in this thesis. It can be helpful, especially 
since we found that parents who received favourable results were less inclined to look 
for additional information on HLA-genotyping and CD by themselves.
In addition, in the case of FDRs, HLA-typing can contribute to predict the individual risk 
to develop CD, which may have consequences for screening. Unfortunately, primary 
prevention by dietary interventions with breastfeeding and early or delayed introduction 
of gluten has proven not to be possible in at risk children39,44. In Chapter 5, we have 
presented the results of a retrospective analysis of CD screening in FDRs. We found a 
high prevalence of CD of 15%, even higher than earlier studies45–47. Several prospective 
studies have demonstrated the natural occurrence of CD in genetically at risk individu-
als39,44,48, with a high prevalence ranging from 5 to 40% depending of the cohort, sex 
and genotype. Extrapolation of these data to older children and adults who are con-
fronted with a family member being diagnosed with CD is however not straight forward. 
In this Chapter 5, we have shown that individual risk depends on the HLA-genotype, 
with HLA-DQ2 homozygosity resulting in the highest risk, therefor warranting closer 
surveillance. Our results suggest that the timing of CD specific antibody testing could be 
individualized depending on the relationship of the FDR with the index patient, the age 
of the FDR at time of the index diagnosis and HLA-type of the FDR. Prospective studies 
with regular screening intervals are needed to further address this issue, especially with 
regard to the adolescent age group. A proposal for a screening algorithm can be found 
in Chapter 5 of this thesis (Figure 3).This would mean, although costly, that HLA-typing 
has its benefits even in this group, not only to rule out (future) CD, but mainly to esti-
mate the risk of developing the disease.
Like FDRs, HLA-typing is also advised to be performed in children with T1DM as part 
of the coeliac screening process. Similar to FDRs, the vast majority of diabetic children 
is HLA-DQ2 and/or DQ8 positive (86%)40. About 7% of them have CD40,49. However, 
the diabetic children seem different than other risk groups, since there is a substantial 
group of children with T1DM who have fluctuating and/or normalizing CD specific an-
tibodies50-52. On the other hand, like FDRs, older age at time of T1DM diagnosis has a 
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protective effect with regard to CD diagnosis53. In Chapter 6, we have shown the ten-
dency in our cohort of diabetic children with CD as well to be younger than the diabetic 
children without CD. The usual female predominance of CD does not appear to be seen 
in other cohorts with T1DM and CD53,54, even though in general there appears to be no 
gender difference in incidence of childhood T1DM55. Maybe the male preponderance is 
by part caused by a higher incidence of males in specific diabetic subgroups, like ado-
lescents older than 13 years of age from European origin55,56. In our cohort however, we 
did not witness this male dominance, maybe due to relatively young age of our cohort 
(mean age 9.7 years).
In Chapter 6, we have demonstrated that when complying with the current ESPGHAN 
guidelines in asymptomatic children with T1DM, 12% of the children have normal duo-
denal mucosa when biopsied after ascertaining a TG2A titer of >3xULN. In accordance 
with our own results and other studies, repetition of serology instead of performing 
endoscopy to retrieve biopsies in these patients seems appropriate50,51. Current follow-
up protocols for children with T1DM include CD specific serology at diagnosis and every 
1-2 years thereafter57. In order to gather evidence on the length and interval of screen-
ing after diagnosis of T1DM prospective studies are needed. The international TEDDY 
(The Environmental Determinants of Diabetes in the Young) birth cohort study, studies 
factors influencing the development of T1DM, but also CD, because of the shared ge-
netic background. It has been shown, that T1DM autoimmunity precedes coeliac auto-
immunity in early childhood in children at high genetic risk of both diseases and that 
preceding islet autoantibodies (IA) significantly increase the risk of subsequent TG2A 
generation58. Data from the PreventCD cohort, shows a higher incidence of CD especial-
ly in multiple IA59. However, the time from IA seroconversion to clinical manifestation 
of T1DM shows a big variation between individuals, ranging from weeks to decades with 
individuals with different types of IAs having the highest risk in the shortest time60, so 
CD can also precede T1DM. One can argue, that screening for IA could be done in coeliac 
children, since it was shown in the TEDDY cohort that genetically susceptible children 
who were diagnosed with T1DM diagnosed due to screening/surveillance have a better 
diabetes quality of life and lower parenting stress post-diagnosis compared to children 
diagnosed with T1DM in the community61.
Future directions
In order to improve health-related quality of life of children with CD, it is important to 
find other ways to achieve early diagnosis and to optimize treatment and follow-up. In 
the next few years, special attention should be given to transition from pediatric to adult 
coeliac care. Ideally, this transition should be a collaborative process involving patients, 
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their parents or caregivers, the physician and the dietician62. Currently, the majority 
of coeliac patients in their twenties and forties who are diagnosed during childhood 
receive no medical or dietary supervision after transition to adulthood, with dietary 
non-compliance and complications such as iron deficiency anaemia and osteopenia as 
a result63. In 2016, the Prague consensus report on this matter was published64, focus-
sing on transfer of full responsibility for the adolescent, discussing dietary adherence 
and consequences of non-adherence and advising adult gastroenterologist on the ap-
proach for patients diagnosed during childhood based on the ESPGHAN2 or NASPGHAN3 
criteria. Efforts should be made to endorse transition programs together with adult gas-
troenterologists. A better collaboration could also mean family programs by organising 
family outpatient clinics where within one family multiple FDRs could get their annual 
check-up whilst the others could be screened at the same time. Both knowledge on CD, 
self-management, family/risk group screening and transition could benefit from deploy-
ing medical applications and robots. Humanoid robots have been introduced in the 
health care domain for both adults65,66 and children67. They could generate a continuous 
awareness of the chronicity of a disease whilst offering the support that is needed at any 
time and at any age. In this respect lessons will be learned from the PAL (Personal As-
sistant for healthy Lifestyle) 4U Project that started in 2015 as part of EU Horizon 2020 
Program to improve child’s diabetes regimen by assisting the child, health professional 
and parent. Another promising innovative example is the MyCyF-app, also funded by 
Horizon 2020, for patients with cystic fibrosis. Its goal is to enable them to monitor the 
disease, change enzyme-treatment and diet if needed and educate patients, caregivers 
and health professionals. Like these chronic illnesses, coeliac follow-up programs could 
also benefit from similar self-management programs. For example, online self-manage-
ment systems can encourage patients to improve participation in their own health care 
by dealing with their symptoms, treatment and lifestyle changes. It can contribute to 
shared decision making between doctor and patient68,69. In CD, moving from traditional 
medical care with annual face-to-face 15-20 minutes visits focussing on complaints, 
growth and blood results to online consultations with questionnaires that also address 
quality of life and dietary adherence might be the way forward. Our research group has 
shown that implementation of eHealth is feasible for children with CD. It is cost saving, 
increases CD-specific health-related quality of life and is satisfactory in the majority of 
patients and parents70. Introducing robots or apps into coeliac care should incorporate 
several domains: 1. Education and information on the disease and treatment, not only 
for the patient and his/her family but also for use at school, restaurants etc, 2. Real-time 
diet evaluation, for example by using barcodes, with regard to gluten content and nutri-
tional value, 3. Chat function with peers and/or professionals if needed (medical doctor, 
dietician, psychologist). Alliance with health science and technology together with the 
national coeliac association is needed in order to complement the needs of patients and 
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Alhoewel coeliakie (CD) een veel voorkomende, maar nog steeds onder gediagnosticeer-
de ziekte is, dient onderzoek zich niet alleen te focussen op de diagnostiek en nieuwe 
behandelmogelijkheden. Het zou zich ook moeten richten op de juiste begeleiding en 
monitoring van patiënten na starten van een glutenvrij dieet (GFD). Daarnaast zouden er 
in het kader van secundaire preventieve evidence-based richtlijnen voor risicogroepen 
dienen te komen om de ziekte zo vroeg mogelijk op te sporen. De vragen die bij aanvang 
van dit proefschrift voorlagen, worden gepresenteerd in Tabel 1, samen met de verza-
melde aanbevelingen.
Tabel 1 Voornaamste conclusies van dit proefschrift
Vragen Bevindingen Aanbevelingen
Houden voedingstekorten aan of 
ontstaan deze bij kinderen met coeliakie 
na start van een glutenvrij dieet?
Voedingstekorten herstellen 
binnen 1 jaar op een glutenvrij 
dieet. 
Na aan jaar zijn standaard 
bloedbepalingen naast coeliakie 
specifieke antistoffen zijn niet nodig.
Kunnen korte dieetvragenlijsten 
infrequente dieetfouten opsporen bij 
kinderen met coeliakie?
De korte dieetvragenlijst 
ontwikkeld door Biagi verschaft 
niet meer informatie dan 
coeliakie specifieke serologie. 
Een gestandaardiseerd dieet-interview 
geeft gedetailleerde informatie over 
dieet(on)trouw, vooral als deze ingevuld 
wordt voor het polibezoek. 
Wat is de impact van HLA-screening bij 
kinderen met risico op het ontwikkelen 
van coeliakie?
Ouders van jonge kinderen 
in gezinnen met coeliakie 
onderstrepen het belang van 
HLA-typering. Zij zouden dit bij 
toekomstige kinderen herhalen.
HLA-typering zou aangeboden moeten 
worden aan kinderen uit risicogezinnen, 
met daarbij behorende uitleg.
Wat is de beste screeningsmethode voor 
eerstegraadsfamilieleden van nieuw 
gediagnosticeerde coeliakie patiënten?
Eenmalige screening kan 
genoeg zijn in adolescente 
broers en zussen en in ouders 
van nieuw gediagnosticeerde 
coeliakie patiënten.
Screening door middel van coeliakie 
specifieke serologie zou met enige 
regelmaat moeten worden aangeboden 
aan alle HLA-DQ2 en/of DQ8 positieve 
eerstegraadsfamilieleden jonger dan 
10 jaar. 
Wanneer moeten duodenumbiopten 
gedaan worden bij kinderen met type1 
diabetes en verhoogde TG2A serologie, 
gezien het feit dat serologie vaak vals 
positief is en/of een spontaan dalende 
trend laat zien bij deze kinderen?
12% van de asymptomatische 
kinderen met T1DM heft 
normale duodenum mucosa 
als zij gebiopteerd worden bij 
een TG2A titer van >3xULN. 
Follow-up door middel van serologie 
in plaats van endoscopie voor het 
verkrijgen van biopten lijkt in deze 




Tot op heden is het glutenvrije dieet de enige behandeling van coeliakie. Alhoewel het 
een bewezen positief effect heeft op de gezondheid van coeliakie patiënten, ontbre-
ken effectieve lange termijn behandelprogramma’s voor zowel kinderen als volwasse-
nen met coeliakie. De behoefte aan deze programma’s om dieettrouw en uitkomsten 
te verbeteren wordt onderkend door verschillende experts1–5, aangezien vertraging van 
het glutenvrij dieet lijkt te leiden tot een verhoogd risico op co-morbiditeit, mortali-
teit en een lagere kwaliteit van leven6,7. In 2016 zijn daarom door kinderartsen-MDL 
in de Verenigde Staten aanbevelingen gepubliceerd voor de behandeling van kinderen 
met coeliakie8, waarin het tekort aan gegevens van goede kwaliteit over dit onderwerp 
werd benadrukt. Momenteel bestaat standaard zorg voor kinderen met coeliakie uit 
regelmatige bezoeken aan een kinderarts(-MDL), met beoordeling van de algemene ge-
zondheid, lengte en gewicht, dieettrouw en bloedtesten inclusief coeliakie specifieke 
antistoffen en andere bepalingen ter beoordeling van tekorten en co-morbiditeit. Het is 
daarbij belangrijk te realiseren dat eerdere publicaties hebben laten zien dat follow-up 
niet plaatsvindt bij alle patiënten, zowel bij kinderen als volwassenen9–12. Onderzoek in 
een pediatrisch cohort uit Israël heeft laten zien dat zogenaamde lost-to-follow-up pati-
enten slecht gecontroleerde ziekte hadden met meer dieet ontrouw en positieve coelia-
kie specifieke antistoffen13. We kunnen alleen maar speculeren of deze non-compliance 
leidt tot meer lange termijn complicaties, aangezien follow-up gegevens gewoonweg 
ontbreken, bij kinderen en volwassenen, maar ook bij onbehandelde en behandelde pa-
tiënten. Het is daarom wezenlijk relevant evidence based richtlijnen te ontwikkelen voor 
follow-up van patiënten met coeliakie, die worden behandeld met een glutenvrij dieet.
Dit was de aanleiding de voedingstekorten te bestuderen die kunnen voorkomen in 
patiënten met coeliakie en die gewoonlijk ook gecontroleerd worden tijdens follow-up. 
De vaak bij diagnose aanwezige tekorten verdwijnen binnen een jaar op een glutenvrij 
dieet, zoals we hebben laten zien in Hoofdstuk 2. Dit betekent dat standard bloed-
testen naast coeliakie specifieke antistoffen niet nodig zijn na een jaar follow-up. Dit 
is een belangrijke bevinding, vanwege de consequenties voor de organisatie van zorg 
voor kinderen met coeliakie, omdat bloedtesten tijd en geld kosten en door sommige 
kinderen als pijnlijk en stressvol worden ervaren. De gevonden tekorten in onze studie 
waren vergelijkbaar in aantal met eerdere studies, behalve vitamine B12 dat veel lager 
was in ons cohort (2%) in vergelijking met eerdere onderzoeken met adolescenten en 
volwassenen (12-41%)14-17. Onze gegevens over schildklierproblematiek (ongeveer 4%) 
zijn ook vergelijkbaar met eerdere studies, met een prevalentie van schildklier auto-
immuniteit (verhoogd TSH of aanwezigheid van thyroperoxidase (TPO) antilichamen), 
hypothyroidie and hyperthyroidie variërend van 10-26%, 2-6% en 1%, respectivelijk18,19. 
De rationale achter het bepalen van de schildklierfunctie tijdens de follow-up zit in de 
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hoge frequentie van schildklier auto-immuniteit bij coeliakie20, maar er is inconsistent 
bewijs over het beschermend effect van het glutenvrij dieet in het ontstaan ervan21–23. 
Op grond van onze resultaten, zou routinematig testen van TSH, de meest gebruikte 
bepaling om te screenen op schildklierziekten, ontmoedigd moeten worden, aangezien 
(tijdelijk) afwijkende resultaten vaak voorkomen zonder afwijkende FT4 waarden. Het 
kan leiden tot overdiagnose en angst bij patiënten en ouders. Schildkliertesten zouden 
alleen gedaan moeten worden bij symptomatische kinderen met een afwijkende groei 
of puberteitsontwikkeling, vermoeidheid, veranderd ontlastingspatroon en eetlust, 
spierpijn of tremoren, ofthalmopatie, thermodysregulatie en veranderde schoolpresta-
ties. Indien nodig, zou FT4 bepaald dienen te worden. Omdat herstel van de mucosa na 
start van het glutenvrije dieet bij kinderen vergelijkbaar lijkt te zijn met volwassenen, is 
onze hypothese dat hetzelfde advies gegeven kan worden aan volwassenen, maar er is 
momenteel geen bewijs om dit te staven.
Om behandeling en follow-up bij kinderen te evalueren is een goede beoordeling van 
dieettrouw nodig, aangezien het dieet de enige behandeling is. Omdat het dieet niet 
altijd makkelijk is om te volgen, is het cruciaal de patiënten te identificeren die het dieet 
wel en niet volgen. Terwijl een uitgebreide beoordeling door een getrainde diëtiste be-
schouwd wordt als de beste manier om dieettrouw te evalueren, is voor deze methode 
veel tijd (20-30 minuten per patiënt) en gespecialiseerd personeel nodig. In Hoofdstuk 3 
hebben we laten zien dat een gestandaardiseerde dieetvragenlijst een goed alternatief 
kan zijn voor het lijfelijke contact met een diëtiste. Een korte vragenlijst, ontwikkeld 
en getest bij volwassenen24 verschafte niet meer informatie over dieettrouw dan anti-
tissue transglutaminase type 2 antistoffen (TG2A). Beiden detecteren niet alle fouten in 
kinderen en tieners met coeliakie. We hebben een verminderde dieet compliance gecon-
stateerd bij adolescenten, hetgeen eerder beschreven is in coeliakie populaties25–27. Ge-
slacht, leeftijd bij diagnose en aanwezigheid van andere gezinsleden met coeliakie beïn-
vloedden de compliance niet, het volgen van een ander dieet naast het glutenvrije dieet 
en de aanwezigheid van klachten na gluteningestie evenmin. Ondanks pogingen hiertoe 
is het ons niet gelukt de vragenlijst in te korten. Door het toenemende gebruik van 
elektronische patiënten dossiers en eHealth tools zou de dieetvragenlijst echter toch 
ingezet kunnen worden in de zorg voor kinderen en jongvolwassenen met coeliakie. 
Routinematig gebruik van deze dieetvragenlijsten, vooral indien ingevuld voorafgaand 
aan een consult, kan de helpen te focussen op valkuilen en problemen met het gluten-
vrije dieet. Het kan de arts inzage geven in mogelijke dieetfouten, de redenen hiervoor 
en wanneer ze optreden. Dit biedt de mogelijkheid tot eventuele benodigde educatie 
en tot steun. Wij verwachten dat dit zal leiden tot verbetering van zorg voor patiënten 
met coeliakie, door hen op de korte termijn te versterken naar een betere dieettrouw, 
en mogelijk op de lange termijn complicaties van ziekte zal verminderen. Het zal niet 
alleen een nuttig instrument blijken in de dagelijkse praktijk, het dieetinterview kan ook 
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gebruikt in prospectieve studies naar lange termijn uitkomsten van coeliakie patiënten 
op een glutenvrij dieet. Nieuwe methoden om gluten immunogene peptiden (GIP) in 
urine en ontlasting te meten zouden hier verder aan bij kunnen dragen28,29. Door middel 
van het meten van GIP kan directe en kwantitatieve gluteninname beoordeeld worden. 
Het kan incidentele dieetfouten opsporen die niet opgepikt worden door de coeliakie 
specifieke serologie en daarmee patiënten identificeren die het dieet niet volgen. Omdat 
GIP analyse alleen gluten kan detecteren wanneer deze een paar dagen voorafgaand 
aan de test ingenomen is, kan ingestie hiervoor gemist worden. GIP bepaling kan nuttig 
zijn voor patiënten die het dieet goed volgen, maar bij wie het TG2 antistoffen positief 
blijven. Als de TG2A-waarde daalt en GIP is bij herhaling negatief, lijkt geruststelling van 
patiënten en ouders op zijn plaats.
De volgende stap in het verbeteren van de gezondheid en kwaliteit van leven voor coe-
liakie patiënten is het verminderen van het aantal gemiste diagnoses. Om dit mogelijk 
te maken is notie van de ziekte en eerder denken eraan belangrijk, zowel bij het publiek 
als bij artsen. Daarbij dient secundaire preventie door vroege diagnose en behandeling 
geoptimaliseerd te worden door de ontwikkeling van screeningsprogramma’s voor ri-
sisogroepen. Betreffende screening zijn de voordelen die het oplevert het meest in het 
oog springend. Voorgaand onderzoek laat enig bewijs zien voor screening strategieën 
ter voorkoming van complicaties en reducering van medische kosten30–32. Echter, voor-
delen en kosteneffectiviteit van screening blijven controversieel33,34. Actieve opsporing 
van patiënten (case finding) kan overwogen worden, alhoewel het algemeen bekend is 
dat het gebruik van symptomen om patiënten te identificeren slechts beperkte waarde 
heeft. Coeliakie gerelateerde klachten komen zowel bij individuen met en zonder coelia-
kie voor35. Aan de andere kant zouden case finding programma’s gebaseerd op sympto-
men bij kinderen een alternatief kunnen zijn voor bevolkingsonderzoek, waar de Medisch 
Ethische Toetsing Commissies in Nederland tegen gekant zijn. Omdat gezondheidsvoor-
delen bij symptomatische kinderen na diagnose en behandeling te verwachten zijn, werd 
toestemming verleend aan de GLUTENSCREEN studie binnen de jeugdgezondheidszorg 
in Noord-Holland. Bij risicogroepen wordt screening op coeliakie aanbevolen door zo-
wel de Nederlandse als Europese coeliakie richtlijnen2,36, aangezien mensen met andere 
auto-immuunziekten zoals type 1 diabetes mellitus (T1DM), auto-immuun schildklier- en 
leverziekten, maar ook syndromen, zoals Down, Turner en Williams syndroom, selectieve 
IgA deficiëntie en eerstegraadsfamilieleden van coeliakie patiënten een hoger risico heb-
ben de ziekte te krijgen. Betrokkenheid van huisartsen in Nederland hierbij is hoogno-
dig, vanwege het feit dat de NHG standaard screening bij eerstegraadsfamilieleden, die 
meestal alleen bij de huisarts onder controle zijn, niet adviseert37.
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Door de hoge negatief voorspellende waarde van HLA-typering, kunnen onnodige on-
derzoeken achterwege blijven bij HLA-DQ2 en DQ8 negatieve mensen. Dit gegeven 
vormt de basis van het advies in de ESPGHAN richtlijn coeliakie om HLA-typering te 
gebruiken als eerste stap in de screening van risicogroepen2. Het percentage van HLA-
DQ2/DQ8 negatieve eerstegraadsfamilieleden is alleen laag, in de cohorten die we in 
dit proefschrift hebben bestudeerd 12.5% (Hoofdstuk 4) en 15% (Hoofdstuk 5), verge-
lijkbaar met andere cohorten38,39. Hetzelfde geldt voor patiënten met diabetes, bij wie 
in verscheidene studies is aangetoond dat de HLA-DQ2 en/of DQ8 haplotypes slechts 
zelden afwezig zijn40–42. Het feit dat HLA-typering nog steeds vrij prijzig is en de uitslag 
bovendien voor veel mensen lastig te interpreteren is, zou ons dit advies in twijfel moe-
ten laten trekken. Aan de andere kant, in deze tijd van shared decision making, is het 
wel of niet weten van het risico niet aan de arts om te bepalen. We hebben laten zien 
dat ouders uit gezinnen waarin coeliakie voorkomt achter HLA-typering staan en dit 
bij toekomstig kinderen zouden herhalen (Hoofdstuk 4). Ze zouden zelfs bereid zijn te 
betalen voor het screenen van hun nakomelingen43. Om te beoordelen of ouders goed 
in staat zijn bij zulke beslissingen betrokken te worden, is het belangrijk om naast hun 
mening ook zicht te hebben op hun begrip van erfelijkheid, wat berucht staat om de 
complexiteit en de erbij behorende opinies. Ondanks de goede kennis van ouders uit 
gezinnen met coeliakie ten aanzien van HLA-typering, mis interpreteert 48% van hen 
een negatieve uitslag (Hoofdstuk 4). Ouders die wisten dat HLA-DQ2/DQ8 nodig is 
voor de ontwikkeling van coeliakie dachten dat er toch een kans was dat hun HLA-DQ2/
DQ8 negatieve kind coeliakie zou kunnen krijgen. Misschien is het moeilijk voor hen om 
aan de gunstige uitslag te wennen met het verdwijnen van het ziekte perspectief in de 
toekomst. Het zou artsen moeten laten achterhalen of ouders de uitslag begrijpen en 
de manier van informatievoorziening laten verbeteren. De informatiebrochure die voor 
dit doel is ontworpen, is als Supplemental material appendix D toegevoegd aan 
dit proefschrift. Het kan helpen, juist bij ouders, die zoals wij zagen, bij een gunstige 
uitslag niet meer geneigd waren extra informatie op te zoeken over HLA-typering en 
coeliakie. Daarbij kan HLA-typering bij eerstegraadsfamilieleden helpen het risico in te 
schatten op het ontwikkelen van coeliakie, hetgeen consequenties kan hebben voor de 
screening. Helaas is primaire preventie door middel van dieet interventies met vroege 
en verlate introductie van gluten niet mogelijk gebleken39,44. In hoofdstuk 5 hebben de 
resultaten gepubliceerd van een retrospectieve analyse van coeliakie screening in eer-
stegraadsfamilieleden. We ontdekten een hoge prevalentie van coeliakie van 15%, zelfs 
hoger dan eerdere studies45–47. Verschillende prospectieve studies hebben laten zien 
hoe vaak coeliakie in erfelijk belaste individuen voorkomt39,44,48, met een hoge preva-
lentie, variërend van 5 tot 40% afhankelijk van het cohort, geslacht en HLA-genotype. 
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Extrapolatie van deze data naar oudere kinderen en ouders, die geconfronteerd wor-
den met een gezinslid met nieuw ontdekte coeliakie, is echter niet zo eenvoudig. In dit 
hoofdstuk 5 hebben we laten zien dat het individuele risico afhangt van HLA-genotype, 
met het hoogste risico bij HLA-DQ2 homozygotie, wat tot striktere controle zou moeten 
leiden. Onze resultaten suggereren dat coeliakie specifieke antistoftesten individueel 
gepland zouden kunnen worden, afhankelijk van de relatie van het eerstegraadsfami-
lielid met de index patiënt, de leeftijd van het familielid ten tijde van de diagnose van 
de index patiënt en het HLA-type van het familielid. Prospectieve studies met geplande 
screeningsintervallen zijn nodig om dit punt verder te onderzoeken, vooral ten aanzien 
van de adolescenten. Een voorstel voor een screeningsalgoritme kan teruggevonden 
worden in hoofdstuk 5 van dit proefschrift (Figuur 3). Dit kan betekenen, dat ondanks 
de hoge kosten, HLA-typering zijn voordelen heeft in deze groep, niet alleen om coelia-
kie (in de toekomst) uit te sluiten, maar vooral om het risico erop in te schatten.
Net als bij eerstegraadsfamilieleden wordt HLA-typering aangeraden bij kinderen met 
type 1 diabetes mellitus als onderdeel van het screeningsproces op coeliakie. Verge-
lijkbaar is het feit dat de meerderheid van de kinderen met diabetes HLA-DQ2 en/of 
DQ8 positief is (86%)40. Ongeveer 7% van hen heeft coeliakie40,49. Daarentegen lijken 
de kinderen met diabetes ter verschillen van de andere risicogroepen, aangezien een 
substantiële groep fluctuerende en/of normaliserende coeliakie specifieke antistoffen 
heeft50-52. Aan de andere kant, net als bij de eerstegraadsfamilieleden beschermt oudere 
leeftijd ten tijde van ontwikkelen van diabetes ten aanzien van coeliakie diagnose53. In 
Hoofdstuk 6, zagen we dezelfde trend van een jongere leeftijd van diabetes kinderen 
met coeliakie ten opzichte van kinderen met diabetes zonder coeliakie. De gebruike-
lijke vrouwelijke overheersing zoals die gezien wordt bij coeliakie lijkt niet te bestaan 
bij eerder beschreven cohorten met type 1 diabetes en coeliakie53,54, alhoewel er in zijn 
algemeenheid geen verschil lijkt te zijn betreffende incidentie van diabetes op de kin-
derleeftijd qua geslacht55. Wellicht dat de mannelijke dominantie te verklaren valt door 
de hogere incidentie van jongens in specifieke diabetes subgroepen, zoals adolescenten 
ouder dan 13 jaar van Europese komaf55,56. In ons cohort, wordt de mannelijke overheer-
sing echter niet gezien, misschien door de relatieve jonge leeftijd van onze groep (mean 
leeftijd 9.7 jaar). In Hoofdstuk 6, hebben we laten zien dat 12% van de asymptomati-
sche kinderen met diabetes type 1 hebben normale duodenum mucosa, wanneer zijn 
conform de huidige ESPGHAN richtlijn gebiopteerd worden bij een TG2-titer van >3x de 
bovengrens van normaal. In overeenstemming met onze resultaten en andere studies 
lijkt herhaling van serologie in plaats van endoscopie ter verkrijging van biopten doel-
matig50,51. Conform de huidige behandelprotocollen voor kinderen met type 1 diabetes 
wordt coeliakie specifieke serologie bij diagnose bepaald en nadien iedere 1-2 jaar57. 
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Prospectieve studies zijn nodig om bewijs te vergaren ten aanzien van de screenings-
duur na de diabetes diagnose en het interval. De internationale TEDDY geboortecohort 
studie (The Environmental Determinants of Diabetes in the Young) bestudeert factoren 
die de ontwikkeling van type 1 diabetes, maar ook coeliakie kunnen beïnvloeden, gezien 
de gemeenschappelijke erfelijke achtergrond. Hierbij werd getoond dat diabetes auto-
immuniteit vooruit loopt op coeliakie auto-immuniteit gedurende de jeugd van kinderen 
met een erfelijke aanleg voor beide ziekten, waarbij vorming van zo genaamde “islet 
antibodies” (IA) de kans op het maken van TG2 antistoffen significant vergroot58. Gege-
vens uit het PreventCD cohort laten een hogere incidentie van coeliakie zien in geval van 
meerdere subtypen IA59. Aangezien de tijd tussen IA seroconversie tot klinische mani-
festatie van T1DM erg kan verschillen van individu tot individu, variërend van weken tot 
decennia60, kan coeliakie echter diabetes vooraf gaan. Het valt te bezien of screening 
met IA gedaan dient te worden in kinderen met coeliakie, omdat erfelijk belaste kinde-
ren bij wie diabetes vastgesteld werd door middel van screening een betere kwaliteit 
van leven hebben en hun ouders minder stress hebben na de diagnose vergeleken bij 
kinderen met diabetes uit de algehele bevolking61.
Toekomstvisie
Om gezondheid gerelateerde kwaliteit van leven van kinderen met coeliakie te verbe-
teren, is het belangrijk manieren te vinden ter bevordering van een vroege diagnose en 
voor optimalisering van behandeling en controle. De aankomende jaren dient speciale 
aandacht te gaan naar transitie van zorg van kind naar volwassen coeliakie zorg. Ideali-
ter zou deze transitie een gezamenlijk proces moeten zijn met patiënten, hun ouders of 
verzorgers, artsen en dietisten62. Momenteel ontvangt de meerderheid van de patiënten 
met coeliakie tussen 20 en 40 jarige leeftijd geen medische of dietetaire zorg na transi-
tie naar volwassenheid, met dieet-ontrouw en complicaties zoals als ijzertekort anemie 
en osteopenie als resultaat63. In 2016, werd het zogenaamde Praag consensus rapport 
ten aanzien van dit onderwerp gepubliceerd64, met focus op het verschuiven van vol-
ledige verantwoordelijkheid naar de adolescent zelf, aandacht voor dieet trouw en con-
sequenties van dieet ontrouw en advies aan MDL-artsen ten aanzien van de aanpak 
van coeliakie patiënten die in hun kindertijd conform ESPGHAN2 of NASPGHAN3 crite-
ria zijn gediagnosticeerd. Er zal gepoogd moeten worden transitie programma’s samen 
met MDL-artsen te ondersteunen. Een betere samenwerking zou kunnen resulteren in 
maatwerk voor gezinnen, met gezinsconsulten waarin een of meerdere gezinsleden 
met coeliakie hun jaarlijkse controle kunnen hebben terwijl de anderen tegelijkertijd 
gescreend kunnen worden op de ziekte.
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Zowel kennis over coeliakie, zelfmanagement, familie en risicogroep screening en tran-
sitie zou gebaat kunnen zijn bij de inzet van medische applicaties en robots. Menselijke 
robots zijn in het gezondheidsdomein zowel bij volwassenen65,66 als bij kinderen67 geïn-
troduceerd. Zij kunnen de continue aanwezigheid van een chronische ziekte onder de 
aandacht brengen en gelijktijdig ondersteuning bieden waar en wanneer dat nodig is, op 
elke leeftijd. Hierbij zou lering getrokken kunnen worden uit het PAL (Personal Assistant 
for healthy Lifestyle) 4U Project dat in 2015 is gestart als onderdeel van het EU Horizon 
2020 Programma dat als doel heeft de zorg voor kinderen met diabetes te verbeteren 
door het kind, de ouder en de gezondheidsprofessional bij te staan. Een ander veel-
belovend en innovatief voorbeeld is de MyCyF-app, ook gefinancierd uit Horizon 2020, 
voor patiënten met taaislijmziekte (cystic fibrosis). Met als doel om ziekte te monitoren, 
enzymtherapie en dieet waar nodig aan te passen en patiënten, verzorgers en profes-
sionals van educatie te voorzien. Net als deze chronische ziekten zouden coeliakie pro-
gramma’s baat kunnen hebben bij vergelijkbare zelfmanagement programma’s. Online 
zelfmanagement programma’s zouden patiënten kunnen laten participeren in hun eigen 
gezondheidszorg door om te gaan met hun klachten, behandeling en leefstijlinterventies. 
Het kan bijdrage aan zogenaamd “shared decision making” tussen patiënt en arts68,69. De 
overgang van ouderwetse medische zorg met jaarlijkse “face-to-face” contacten van 15-
20 minuten met de focus op klachten, groei en bloeduitslagen naar online consulten met 
vragenlijsten over kwaliteit van leven en dieettrouw kan een sprong voorwaarts worden. 
Onze onderzoeksgroep heeft laten zien dat implementatie van eHealth is haalbaar bij 
kinderen met coeliakie. Het bespaart kosten, vergroot coeliakie specifieke gezondheid 
gerelateerde kwaliteit van leven en stelt de meerderheid van de patiënten tevreden70. 
De introductie van robots en apps in de coeliakie zorg zou meerdere domeinen moeten 
behelzen: 1. Educatie en informatie over de ziekte en behandeling, niet alleen voor de 
patiënt en zijn/haar gezin, maar ook voor gebruik buitenshuis op school, in restaurants 
etc., 2. Realtime dieetbeoordeling, bijvoorbeeld door het scannen van barcodes, met be-
trekking tot gluten gehalte en voedingswaarde, 3. Chat functie met leeftijdsgenoten en 
of professionals indien nodig (arts, diëtiste, psycholoog). Samenwerking tussen gezond-
heidszorg, technologische partners en de Nederlandse Coeliakie Vereniging is nodig om 
de behoeften van patiënten aan te vullen en de beste eHealth oplossing te vinden.
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A. LiST OF ABBrEviATiONS
CD Coeliac disease
TG2A Anti-tissue transglutaminase type 2 antibodies
HLA Human leucocyte antigen
T1DM Type 1 diabetes mellitus
EMA Anti-endomysium antibodies
DGPA Deamidated gliadin peptide antibodies
ESPGHAN European Society for Paediatric Gastroenterology, Hepatology and Nutrition
GFD Gluten-free diet
FDRs First degree relatives
ULN Upper limit of normal
ID Iron deficiency
IDA Iron deficiency anemia
NIH National Institutes of Health
NICE National Institute for Health and Care Excellence
NASPGHAN North American Society for Paediatric Gastroenterology, Hepatology  
and Nutrition
LUMC Leiden University Medical Center
FT4 Free thyroxin
TSH Thyroid stimulating hormone
AbTPO Thyroperoxidase antibodies
DQ+ HLA-DQ2 and/or DQ8 positive
DQ- HLA-DQ2 and/or DQ8 negative
HRQoL Health related quality of life
HADS Hospital Anxiety and Depression Scale
TAPQOL TNO-AZL preschool children quality of life questionnaire
ROC Receiver operating characteristics
CoN Cut-off values for normality
GIP Gluten immunogenic peptides
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1 Dietary interview, written version.
 − Between brackets number of points per answer, leading to scores:
 − 0-2 strict gluten-free diet
 − 3-20 gluten-free diet with important errors
 − 21-84 gluten-free diet not followed
1 Is your child on a gluten-free diet (GFD)? Yes(84)/No(0)
If no, why isn’t your child on a GFD? (tick appropriate answers)
 − Because my child doesn’t have coeliac related complaints
 − Because it is too complicated
 − Because it is too expensive
 − Some other reason, being …
 Questionnaire ends here if answer was no.
2 Does your child eat gluten accidentally? Yes/No
If yes: (tick appropriate answer)
 − Every day (2)
 − Once a week (1)
 − Once a month (0)
 − Once a year (0)
3 Does your child eat gluten intentionally? Yes/No
If yes, this consists of: (tick appropriate answer)
 − Bread/cereals: daily (5), weekly (4), monthly (2), once a year (0)
 − Pastry: daily (5), weekly (4), monthly (2), once a year (0)
 − Pizza: daily (5), weekly (4), monthly (2), once a year (0)
 − Oliebollen (traditional Dutch deep-fried solid doughnuts eaten during New Year’s 
Eve and fun fairs): daily (5), weekly (4), monthly (2), once a year (0)
 − Deep-fried snacks: daily (3), weekly (2), monthly (1), once a year (0)
 − Candy bars, candy, crisps, nuts: daily (2), weekly (1), monthly (0), once a year (0)
 − Other food such as … daily (3), weekly (2), monthly (1), once a year
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If yes, my child eats gluten intentionally: (tick appropriate answers)
 − At home
 − When he/she is with other family (like grant parents)
 − When he/she is with friends
 − At special occasions (birthday, party etc)
 − When eating out
 − At school/work
 − During sport activities
 − During camp
 − During holidays
4 If there is a treat at school or at work, my child will eat the treat even if it might con-
tain gluten. Yes(2)/No(0).
5 We’ll discuss the GFD with the person taking care of the meal provided for my child, 
if my child will eat somewhere else.Yes/No.
If no, we do not do so: (tick appropriate answers)
 − On holiday (3)
 − On a school trip (3)
 − On camp (3)
 − When staying overnight (2)
 − At a party (1)
6 At home, my child is the only one on a GFD. Yes/No.




7 Besides gluten-free products, there are also gluten containing products available at 
our home. Yes/No.
If yes:
 − The gluten containing products are stored separately from the gluten-free prod-
ucts. Yes(0)/No(2).
 − Other people, who are not on a GFD, can use the gluten-free butter and spread-
able sandwich toppings. Yes/No.
 − If yes, is this done with clean utensils? Yes(0)/No(2).




8 Gluten-free food is always prepared with clean hands, worktop and materials. Yes(0)/
No(2).
9 When needed, gluten-free food is prepared with a personal toaster, bread box, deep 
fryer or baking tin. Yes(0)/No(2).
10 My child eats gluten-free bread. Yes/No.
If yes, this bread is:
 − Home baked, using flour with a ‘gluten-free’ label or logo. Yes/No.
 − Bought as prepacked bread. Yes(0)/No(5).
 − Bought at a local bakery, who makes the bread by itself. Yes(2)/No(0).
If no, why not:
 − My child does not eat bread. Yes/No.
 − My child eats gluten containing bread. Yes(5)/No(0).
11 My child only eats pasta products with a gluten-free label or logo on the packaging. 
Yes(0)/No(3).
12 My child only eats pastries and cereals with a gluten-free label or logo on the packag-
ing. Yes(0)/No(3).
13 My child eats naturally gluten-free flour (like corn, rice, buckwheat, oats, quinoa, 
teff). Yes/No.
If yes, only with a gluten-free label or logo on the packaging. Yes(0)/No(3).
14 My child eats food containing wheat starch. Yes/No.
If yes: (tick appropriate answer)
 − Every day (2)
 − Once a week (1)
 − Once a month (0)
 − Once a year (0)
15 My child eats food containing gluten-free wheat starch. Yes/No.
16 My child eats food with a label “may contain traces of gluten or wheat”. Yes/No.
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If yes: (tick appropriate answer)
 − Every day (2)
 − Once a week (1)
 − Once a month (0)
 − Once a year (0)
17 My child eats food with a label “prepared in an environment where gluten/wheat is 
processed”. Yes/No.
If yes: (tick appropriate answer)
 − Every day (2)
 − Once a week (1)
 − Once a month (0)
 − Once a year (0)
18 My child drinks gluten containing beer. Yes/No. (only presented to children > 12 years)
If yes: (tick appropriate answer)
 − Every day (2)
 − Once a week (1)
 − Once a month (0)
 − Once a year (0)
19 If my child has to use medication, we make sure it is gluten-free. Yes(0)/No(1).
20 If we do not know that certain food is gluten-free:
 − We’ll check whether it has a gluten-free label or logo. Yes/no.
 − We’ll check whether it has a gluten-free label from the supermarket. Yes/no.
 − We’ll read the ingredients and decide whether it is gluten-free. Yes/no.
 − We’ll cross-check is with the Livaad list (List of gluten-free food, provided by the 
Dutch Coeliac Society). Yes/no.
 − We’ll ask the manufacturer. Yes/no.
 − My child will eat it and we will observe whether he/she get complaints. Yes/no.
21 If my child eats something with gluten, he/she gets complaints. Yes/no.
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If yes: (tick appropriate answers)
 − Abdominal pain. Yes/no.
 − Diarrhea. Yes/no.
 − Vomiting. Yes/no.
 − Fatigue. Yes/no.
 − Loss of appetite. Yes/no.
 − Something else …
22 We believe that we have sufficient knowledge on the GFD. Yes/no.
23 I am worried whether my child’s diet contains enough nutrients (like proteins, fat 
and vitamins). Yes/no.
24 It is important for me to have contact with a dietician about my child’s diet on a 
regular basis. Yes/no.
If yes: (tick appropriate answer)
 − Once a year
 − Once every 2 years
 − Once every 5 years
 − Other time interval: …
 − I would like to discuss: …
25 It is important for me to have contact with a doctor about my child’s diet on a regular 
basis. Yes/no.
If yes: (tick appropriate answer)
 − Once a year
 − Once every 2 years
 − Once every 5 years
 − Other time interval: …
 − I would like to discuss: …
26 My child is on another diet besides the GFD. Yes/No.
If yes: (tick appropriate answer)
 − Lactose free
 − Cow’s milk free
 − Other …
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2 Short dietary questionnaire
Between brackets number of points per answer, leading to scores:
 − 0-2 strict gluten-free diet
 − 3-14 gluten-free diet with important errors
 − 15 gluten-free diet not followed
1 Is your child on a gluten-free diet (GFD)? Yes(15)/No(0)
Questionnaire ends here if answer was no.
2 Does your child eat gluten intentionally? Yes(15)/No(0)
If yes, my child eats gluten intentionally: (tick appropriate answers)
 − At home
 − When he/she is with other family (like grant parents)
 − When he/she is with friends
 − At special occasions (birthday, party etc)
 − When eating out
 − At school/work
 − During sport activities
 − During camp
 − During holidays
3 We’ll discuss the GFD with the person taking care of the meal provided for my child, 
if my child will eat somewhere else. Yes(2)/No(0).
4 The gluten containing products are stored separately from the gluten-free products. 
Yes(0)/No(2).
5 Other people, who are not on a GFD, can use the gluten-free butter and spreadable 
sandwich toppings. Yes(2)/No(0).
6 When needed, gluten-free food is prepared with a personal toaster, bread box, deep 
fryer, baking tin. Yes(0)/No(2).




8 My child eats food containing wheat starch. Yes(2)/No(0).
9 My child eats food with a label “may contain traces of gluten or wheat”. Yes (2)/No(0).
10 My child eats food with a label “prepared in an environment where gluten/wheat is 
processed”. Yes(2)/No(0).
11 If my child has to use medication, we make sure it is gluten-free. Yes(0)/No(2).
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Bij uw kind en/of bij u wordt onderzoek gedaan naar coeliakie of is coeliakie vastgesteld. 
Vaak maakt HLA-typering deel uit van dit onderzoek. Deze folder is gemaakt voor 
patiënten en hun ouders, die geïnteresseerd zijn in de achtergrond van dit onderzoek. 
Een aantal termen wordt uitgelegd en de betekenis van de uitslag wordt besproken.
Genetica
Coeliakie is de meest voorkomende voedselintolerantie in de Westerse wereld; meer dan 
1 op de 100 kinderen heeft coeliakie. Erfelijke factoren spelen een belangrijke rol bij de 
ontwikkeling van deze ziekte. Voordat we dieper in gaan op het onderwerp HLA-typering 
bij coeliakie, wordt eerst de achtergrond van de erfelijkheidsleer, de genetica besproken
DNA is opgebouwd uit genen. Een gen codeert voor een bepaalde eigenschap. Van elk 
gen hebben we één variant van onze moeder en één variant van onze vader. De genen 
liggen als compleet erfelijk materiaal opgeslagen in vrijwel iedere cel van ons lichaam. 
1 Basis — Wat is genetica eigenlijk?
Genetica is een gebied in de natuurwetenschappen. Onderzoekers in de genetica houden zich bezig met de overerving 
van erfelijke eigenschappen van de ene generatie op de volgende. Hoe een organisme er uit ziet, zich gedraagt en hoe 
het zich voortplant, wordt bepaald door zijn/haar erfelijk materiaal. Het erfelijk materiaal is opgebouwd uit genen. Dit 
zijn een soort bouwsteentjes die samen het DNA vormen. In je DNA (en dus in je genen) zitten codes ‘verborgen’. Deze 
codes geven instructies voor bijvoorbeeld bloedgroep, haarkleur, maar ook voor aanleg voor bepaalde ziekten.
Figuur 1  Schematische weergave van een karyotype (=chromosomenpatroon) van een man (XY; vrouwen hebben 
XX). Bedenk dat steeds de ene helft van het chromosoompaar van de vader afkomstig is, en de andere 
helft van de moeder. Op chromosoom 6 (cirkel) liggen de coeliakiegenen.
1 2 3 4 5
6 7 9 10 12118
13 14 16 181715
19 20 22 YX21
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Natuurlijk bestaan er uitzonderingen op die regel. Rode bloedcellen bijvoorbeeld, heb-
ben geen kern en dus ook geen DNA. Een andere uitzondering wordt gevormd door 
ei- en zaadcellen. Zij hebben van elk gen maar één variant (in plaats van twee). Bij de 
bevruchting van de eicel door een zaadcel smelten de genen weer tot een set van twee 
varianten samen. Het totale DNA en dus het totale genen pakket, is verdeeld over 46 
chromosomen, waarvan er 23 uit vaderlijk DNA en 23 uit moederlijk DNA bestaan. De 
genen die coderen voor een bepaalde eigenschap liggen bij ieder mens op precies 
dezelfde plaats op een chromosomenpaar (zie Figuur 1).
De inhoud van de informatie op beide chromosomen van een paar kan echter wel ver-
schillend zijn. Zoals gezegd, hebben we van elk gen twee varianten; ook wel twee allelen 
genoemd. Een allel is een variant van een eigenschap. De 2 aanwezige allelen van een 
eigenschap kunnen gelijk zijn,bijvoorbeeld voor blauwe of voor bruine ogen (dit noemen 
we homozygoot, zie Figuur 2). Ze kunnen ook verschillen, bijvoorbeeld een allel voor 
blauwe ogen en een allel voor bruine ogen (dit noemen we heterozygoot). Als de allelen 
identiek zijn, is de uitkomst duidelijk, als de twee allelen coderen voor een verschillende 
oogkleur, zal de uiteindelijke oogkleur van het individu bepaald worden door het sterk-
ste, dominante allel (bruin).
Overerving van een genetische eigenschap
De overerving van een genetische eigenschap is in Figuur 3 schematisch weergegeven 
met een voorbeeld. Elk van beide ouders heeft in dit geval twee verschillende varianten 
van een eigenschap. De varianten noemen we a en b, c en 9. Een kind erft van elke 
ouder één chromosoom (iedere ei- en zaadcellen heeft slechts 23 chromosomen). Hij/zij 
erft dus van beide ouders één variant . Uiteindelijk kunnen er vier verschillende nieuwe 
combinaties ontstaan. De kans dat vervolgens een kind geboren wordt met dezelfde 
combinatie als zijn oudere broer of zus, is 25%. Als de moeder twee maal variant a heeft, 
zal elk kind in ieder geval ook variant a hebben, plus een variant van hun vader. Als beide 
ouders twee maal variant c hebben, zullen de kinderen ook twee maal variant c hebben.
Figuur 2  Twee maal een schematische weergave van chromosoompaar 6. De stippen geven de locatie van 
een gen op een chromosoom aan. De allelen op het linkerchromosoom zijn identiek; het individu is 
homozygoot voor de eigenschap (bijvoorbeeld 2x blauwe ogen). Rechts zijn de genen verschillend; 





Zoals reeds beschreven in tekstbox 1, kunnen onze genen ook coderen voor de vatbaar-
heid voor bepaalde ziekten. Het is onderzoekers opgevallen dat coeliakie vaak voorkomt 
in bepaalde families en in bepaalde bevolkingsgroepen. Zo werd ontdekt, dat het HLA-
gen een belangrijke rol speelt in de ontwikkeling van coeliakie. HLA staat voor Humane 
(menselijke) Leukocyten (witte bloedcellen) Antigenen (karakteristieken). HLA-genen zijn 
nodig voor de opbouw van ons afweersysteem. Ze zijn onder te verdelen in klasse I en 
klasse II.
Coeliakie is geassocieerd met de HLA-klasse-II genen. Deze genen coderen voor zoge-
naamde HLA-II-moleculen. Deze moleculen worden ingebouwd op het oppervlak van 
bepaalde witte bloedcellen, antigeen presenterende cellen geheten. Ze spelen een be-
langrijke rol in ons afweersysteem, omdat ze onderscheid kunnen maken tussen alles 
wat lichaamseigen (veilig) en lichaamsvreemd (potentieel bedreigend) is. Als zij lichaams-
vreemd materiaal gevonden hebben, zullen zij dit ‘verklikken’. Dit doen ze door de li-
chaamsvreemde eiwitmoleculen (maar ook virussen en bacteriën, omdat zij voor een 
deel uit eiwitten bestaan), te binden aan een HLA-II-molecuul op hun celoppervlak. 
Vervolgens presenteren ze de eiwitten aan een andere ‘afdeling’ van het afweersys-
teem; de T-cellen (CD4+ T-helper cellen). Deze T-cellen kunnen onderscheid maken tus-
sen daadwerkelijk bedreigende vreemde eiwitten en eigenlijk niet bedreigende vreemde 
eiwitten, zie tekstbox 2. Ons voedsel bijvoorbeeld, bestaat uit een scala aan lichaams-
vreemd materiaal, waarvan het gros niet bedreigend voor ons is maar zelfs gezond! In 
de eerste levensjaren ontwikkelt een kind tolerantie voor zulke lichaamsvreemde, maar 
niet bedreigende eiwitten. Tijdens dit proces wordt de T-cellen aangeleerd deze eiwit-
ten niet te zien als bedreigend. Want als dit wel gebeurt, start een keten van reacties, 
met als einddoel de vernietiging van het betreffende eiwit. Deze afweerreactie is dus 
Figuur 3  Een schematische weergave van genen die coderen voor een willekeurige eigenschap. Beide ouders 
hebben twee unieke varianten van de eigenschap. Bij voortplanting tussen deze man en vrouw is de 








bedoeld om het lichaam te beschermen. Bij iemand met coeliakie leidt het eten van 
gluten tot een afweerreactie in de dunne darm, met beschadiging van de darmwand 
als gevolg (vlokatrofie). Waarom het afweersysteem bij deze mensen op gluten reageert, 
is nog niet geheel duidelijk. Mogelijk ontwikkelen deze patiënten geen tolerantie voor 
gluten, of verliezen zij juist hun tolerantie.
HLA-DQ2 en HLA-DQ8
Er bestaan vele verschillende HLA-II-moleculen. Ze verschillen van elkaar qua vorm en 
dus ook qua functie. Elke vorm heeft een eigen naam gekregen. Gluten past precies op 
HLA varianten “DQ2” en “DQ8”, die dan ook een belangrijke rol spelen bij coeliakie.
2 Ezelsbruggetje
Met wat fantasie is een HLA-II-molecuul voor te stellen als een ober met een presenteerblaadje, of “HLA-DQ2/DQ8”, 
waarop alleen een glas cola van het merk “gluten” past. De ober presenteert dit glas cola aan zijn klanten. Er lopen 
echter ook politieagenten op het terras rond, de “T-cellen”. Zij houden de boel in de gaten. Normaal levert het serveren 
van een colaatje van het merk “gluten” geen problemen op. Bij mensen met coeliakie zien de T-cellen de gluten als 
bedreigend (een verboden colamerk) en geven ze een seintje aan hun collega-afweercellen om de boel op te ruimen 
m.b.v. antistoffen tegen o.a. gluten (zie Figuur 4).
Figuur 4  Gluten (1) bevinden zich, na een broodmaaltijd, in de dunne darm. HLA-DQ2/DQ8 (gele ober) 
presenteert gebonden gluten (2) aan de T-cel (politieman). De T-cel herkent: ‘HLA-DQ+gluten’ 
en geeft een signaal af aan collega B-cel (4). Dit is het begin van een afweerreactie, waarbij 
antistoffen tegen o.a. gluten worden aangemaakt (5&6).
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Nu gaan we de opgedane kennis over genetica en HLA-II-moleculen combineren. In-
middels weten we dat we van elke genetische eigenschap twee allelen (varianten) heb-
ben. Zo hebben we dus ook twee allelen die coderen voor twee varianten van HLA-II-
moleculen, van beide ouders één. De verantwoordelijke genen liggen op chromosoom 
6. Om te onderzoeken of iemand HLA-DQ2 en/of HLA-DQ8 heeft, worden alle genen die 
coderen voor de HLA-II-moleculen onderzocht.
Een combinatie van HLA-typen die kan voorkomen is bijvoorbeeld DQ2 met DQ4 (notatie 
DQ2/DQ4). DQ2 geeft risico op coeliakie, maar DQ4 niet. Deze persoon is heterozygoot 
voor HLA-DQ2 omdat hij/zij maar één kopie van DQ2 heeft, met daarnaast een andere 
variant van HLA-DQ. De combinatie DQ2/DQ2 betekent dat de persoon homozygoot is 
voor DQ2 (zie Figuur 2).
Risicoprofiel
Aanwezigheid van één HLA-DQ2 of -DQ8 molecuul (heterozygoot) geeft een klein ver-
hoogd risico op coeliakie. Indien er sprake is van homozygositeit (dus twee maal HLA-
DQ2 of HLA-DQ8) is het risico verder verhoogd. Daarnaast geeft HLA-DQ2 een groter 
risico op coeliakie dan HLA-DQ8, dus geeft de combinatie DQ2/DQ8 een hoger risico 
dan DQ8/DQ8, maar is het risico in het geval van DQ2/DQ2 het hoogst. Hoeveel hoger 
het risico precies is, verschilt per bevolkingsgroep. Dat het hebben van HLA-DQ2 en/of 
HLA-DQ8 geen 100% garantie geeft op het ontwikkelen van coeliakie komt doordat deze 
genen niet de enige genen zijn die een rol spelen in de ontwikkeling van coeliakie. Uit 
onderzoek is gebleken dat meer dan een kwart van de Nederlandse bevolking HLA-DQ2 
en/of HLA-DQ8 heeft, zonder dat ze ooit coeliakie zullen ontwikkelen! De bijdrage van 
de HLA-II-genen aan het genetisch bepaalde risico op coeliakie is ongeveer 40%. De 
overige 60% wordt toegeschreven aan andere, voor een deel nog onbekende, omgev-
ingsfactoren en genen (Figuur 5).












Waarom vinden we het dan toch zinvol om een HLA-typering uit te voeren? Dat komt 
door de hoge negatief voorspellende waarde van de test. Hiermee wordt bedoeld dat een 
negatieve uitslag, dus afwezigheid van HLA-DQ2 en HLA-DQ8, betekent dat de kans 
op ontwikkeling van coeliakie verwaarloosbaar klein is. Het risico op coeliakie van een 
eerstegraads familielid van een patiënt met coeliakie zonder dat we weten wat het HLA-
type van dit familielid is, wordt geschat op ongeveer 10%. Als dit familielid een HLA-
typering laat doen, en hij/zij blijkt geen HLA-DQ2 en HLA-DQ8 te hebben, weten we dat 
dit familielid geen risico op coeliakie heeft (Tabel 1). Dit betekent dat verder onderzoek 
naar coeliakie bij deze persoon niet meer nodig is. Aan de andere kant is het verhoogde 
risico op coeliakie bij aanwezigheid van de genen voor HLA-DQ2 en/of –DQ8 een aan-
leiding deze personen (jaarlijks) te controleren op ontwikkeling van de ziekte. Zo hopen 
we coeliakie in een vroeg stadium te ontdekken, waarbij de gevolgen van het eten van 
gluten voorkomen kunnen worden door op tijd te starten met een glutenvrij dieet.
Tabel 1  Risico op coeliakie geassocieerd met HLA-DQ2 en -DQ8, in de algemene populatie en bij 
eerstegraads familieleden van een patiënt met coeliakie.
DQ Risico 
Algemene populatie DQ2 en/of DQ8 +
DQ2 en DQ8 -
2%
0%
Eerstegraads familielid DQ2 en/of DQ8 +
DQ2 en DQ8 -
>15%
0%
Wat hebben wij nodig voor een HLA-typering?
Bijna al onze lichaamscellen bevatten DNA. Cellen die zich goed lenen voor DNA-onder-
zoek zijn de witte bloedcellen. Daarom wordt voor DNA-onderzoek meestal een buisje 
bloed afgenomen. Het is ook mogelijk om ander lichaamsmateriaal, zoals wangslijmv-
lies, te gebruiken. Helaas is de kans dat de HLA-typering mislukt dan een stuk groter.
Conclusie
Een HLA-typering is zinvol als u een eerstegraads familielid heeft met coeliakie. Als de 
uitslag positief is (HLA-DQ2 en/of HLA-DQ8 is aanwezig) zegt dit nog niet dat uw kind/u 
coeliakie zal ontwikkelen. Het risico is echter wel verhoogd. In dit geval raden wij aan om 
een normaal dieet te volgen en bij kinderen regelmatig screening op coeliakie specifieke 
antistoffen te laten verrichten. Indien de uitslag negatief is (HLA-DQ2 en HLA-DQ8 zijn 
afwezig), zal uw kind/u geen coeliakie ontwikkelen en is verdere controle niet nodig.
Handige websites;
 − www.coeliakiepoli.nl, de website van de coeliakiepoli van het LUMC.





Dit proefschrift liep parallel aan mijn ontwikkeling binnen de kindermaag-darm-leverz-
iekten tot nu toe en heeft me op allerlei vlakken veel gebracht. Het leerde me doorzetten 
en onderhandelen en leverde me wetenschappelijk inzicht en kennis over statistiek op. 
Dit proefschrift is het resultaat van de samenwerking met velen, aan wie ik dank ver-
schuldigd ben. 
In de eerste plaats de kinderen met coeliakie en hun ouders, eerst in het LUMC in Leiden 
en later in het Rijnstate in Arnhem. Het moeten leven met deze chronische ziekte en de 
erbij horende dagelijkse beperkingen was en is nog steeds mijn belangrijkste motivatie 
om de zorg op basis van onderzoek te verbeteren.
Natuurlijk was het een voorrecht te mogen leren van zoveel mensen, die mij hebben 
gevormd op zowel medisch inhoudelijk, wetenschappelijk als menselijk vlak.
PrOF. dr. E.H.H.M. rings, beste EdMOnd, je nam het stokje als mijn promotor over van 
Frans waLTHEr en HEnriETTE dELEMarrE na je komst naar Leiden. Jouw scherpe en 
rustige analyse van mijn werk waren erg waardevol.
dr. M.L. MEarin, lieve Luisa, zonder jou zou ik hier niet zijn beland. Wat een voorrecht 
om met jou te mogen werken. Je hebt me geleerd op te komen voor mezelf, oog te 
houden voor anderen en waardering uit te spreken. Je zorgde ervoor dat ik begon bij de 
kinderMDL en introduceerde me binnen de (inter)nationale coeliakie wereld. Ik bewon-
der je kennis, creativiteit en doorzettingsvermogen en hoop ook hierna met je samen te 
mogen blijven werken. 
Collega’s van de afdeling kinderMDL van het LUMC: uit het oog betekent niet uit het 
hart. Dank yvOnnE wiJKHuisEn en ingE durMus, die mij na vertrek naar Arnhem te 
hulp schoten bij vragen. JOaCHiM sCHwEizEr, dank voor alles wat je me als kinderarts 
in opleiding en later als fellow hebt geleerd. Dank voor het mogen afkijken van je didac-
tische vaardigheden: ik pluk daar nu als opleider de vruchten van. Ook aan de mensen, 
die net als ik inmiddels niet meer in Leiden werken, ben ik veel dank en gezelligheid 
verschuldigd. sabinE vriEzinga, wat een mooi eerste internationaal congres was het in 
Stockholm. Het was er een van velen, veel succes in je inmiddels al niet meer zo nieuwe 
carrière. MaaiKE sCHaarT, wat was het fijn er een fellow bij te hebben. nEL MOurad, als 
oude rot in het vak nog promoveren, wat een inspiratiebron was dat!
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Collega’s van de afdeling kinderMDL van het ErasmusMC: de start van mijn kinder-
MDL-carrière begon bij jullie en dat smaakte naar meer. Beste HanKJE, Lissy, JEssiE en 
wiLLiE, bedankt voor alles. Lieve JEssiE, wat was het fijn om een jaar met jou als fellow 
te werken, je maakte me wegwijs in dat grote, voor mij onbekende ziekenhuis. Heel veel 
succes in het verre Toronto, we missen je hier. 
Collega’s van de afdeling kindergeneeskunde van het Rijnstate: het klikte van beide 
kanten toen ik solliciteerde als nog niet klare kinderarts-MDL. Jullie hebben even op mijn 
komst en mijn promotie moeten wachten, maar dan hebben jullie (hopelijk) ook wat! In 
het bijzonder dank aan EvELinE en diana, bij jullie beiden heb ik meestal aan één woord 
genoeg. EvELinE LEiJn, wat een kennis heb je in huis, juist buiten de kinderMDL stond je 
me ook bij. diana COrnELissEn, we vullen elkaar als opleiders goed aan. Als ik iets heb 
bedacht (en verwoord), heb jij het vaak al uitgevoerd! Dank ook aan PETra van sETTEn, 
met wie ik de passie voor wetenschap deel. Dank voor de samenwerking op het raakvlak 
van endocrinologie en MDL. 
Arts-assistenten in het Rijnstate: het is een voorrecht om jullie opleider te mogen zijn 
vanwege het vertrouwen dat jullie mij schenken. Dank dat ik van jullie mag leren: jullie 
nieuwsgierigheid houdt mij scherp en leert me dat een onderzoekende en frisse geest 
nodig is om verder te komen in ons vak. 
Alle collega’s van de MDL in het Rijnstate, het is prettig samenwerken met jullie, ik voel 
me echt onderdeel van het team. Dank PETEr waHab voor het delen van je kennis, niet 
alleen op coeliakie gebied, maar ook in de IBD wereld kan ik veel van je leren. Dank 
JOrdy burgEr, vooral voor de gezelligheid tijdens de ICDS. 
Alle student-onderzoekers zonder wie ik niet zover gekomen was: iris, MariJE, niCKy en 
anOuK, dank.
Omdat er meer is dan werk alleen, ook dank aan alle mensen daarbuiten: vrienden van 
vroeger uit Utrecht en Den Haag, en nu in Arnhem. Mijn jaarclub: fijn dat we nog altijd 
contact hebben en dingen met elkaar kunnen delen! (Oud) Buren: het spreekwoord is 
er niet voor niets. JudiTH en MiCHiEL, jullie hebben voor ons de plek overgenomen van 
PauL en bEaTriCE. Mijn tennismaatjes uit Arnhem, dank voor de ontspanning die jullie 
mij met tennis bieden. 
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Als laatste natuurlijk alle lof voor mijn familie. Ik kwam terecht in een betrokken, lieve 
en actieve schoonfamilie, die met de Kappetijns nog verder werd uitgebreid. Helaas 
heeft mijn schoonvader PiETEr LOOs dit proefschrift niet meer mee mogen maken, ik 
weet zeker dat hij trots vooraan gezeten zou hebben. HarM-Jan en birgiTTa, samen 
met sTELLa, ELisE en axEL delen we veel. birgiTTa, wat ben ik blij met je als schoonzus 
en paranimf! FranK, wEndELa, rOsaLiE, CaTELiJnE en FLOrian, dank voor jullie steun 
vanuit de Verenigde Staten, jammer dat jullie er niet bij kunnen zijn. MaTTHiJs en JuLia, 
mijn nicht en gevoelsmatige zus die ik niet had, zonder jullie zouden in elk geval onze 
vakanties een stuk minder leuk zijn. Mijn ouders, dankzij jullie ben ik wie ik geworden 
ben. Dank voor jullie steun en vertrouwen in mij. 
Afsluitend de grootste dank aan MEnnO, mijn steun en toeverlaat sinds het einde van 
onze studententijd. We vullen elkaar goed aan en stimuleren de ander het beste uit onze 
levens te halen! Je hebt veel voor mijn carrière over gehad, ik hoop jou in de jouwe nog 
lang te mogen ondersteunen. En wiLLEMiJn, sJOErd en TEun: dank voor jullie geduld en 




MargrEET wEssELs werd op 5 april 1976 geboren in Almelo. 
In 1994 deed ze eindexamen VWO aan het OSG Erasmus te 
Almelo, waarna zij door middel van naplaatsing toegelaten 
werd tot de studie Geneeskunde aan de Rijks Universiteit 
Utrecht. Tijdens haar studie deed zij een onderzoeksstage 
in Vancouver, Canada, naar late complicaties van been-
mergtransplantaties en deed zij een coschap dermatologie 
in het Tygerberg ziekenhuis te Kaapstad, Zuid-Afrika. Na haar coschappen werkte zij in 
2001 eerst enkele maanden als consultatiebureau arts in Breda. Van oktober 2001 tot 
oktober 2003 werkte zij als ANIOS kindergeneeskunde in het Diakonessen Ziekenhuis 
te Utrecht en het Leids Universitair Medisch Centrum te Leiden, alwaar zij op 1 oktober 
2003 startte met de opleiding tot kinderarts. Haar perifere stage deed zij in het Reinier 
de Graaf Gasthuis te Delft. In februari 2009 werd zij geregistreerd als kinderarts. Ze 
werkte vervolgens als waarnemend kinderarts in het Juliana Kinderziekenhuis te Den 
Haag tot aan de start van haar fellowship kindermaag-darm-leverziekten in het Eras-
musMC te Rotterdam, locatie Sophia Kinderziekenhuis, in juni 2009. Vanaf 1 oktober 
2010 zette zij dit fellowship voort in het Leids Universitair Medisch Centrum, gecom-
bineerd met de start haar promotie onderzoek. Naast het onderzoek dat zij deed voor 
dit proefschrift, coördineerde zij de opzet van een biobank voor kinderen met coeliakie 
met gestandaardiseerde opslag van zowel biomateriaal als patiëntgegevens. Daarnaast 
was zij betrokken bij een onderzoek naar de uitkomsten van een eHealth systeem voor 
kinderen die onder poliklinische controle zijn voor coeliakie. Op 15 september 2012 werd 
zij geregistreerd als kinderarts-MDL. Sinds augustus 2013 werkt zij in die functie in het 
Rijnstate Ziekenhuis te Arnhem. Ze is er tot op heden wetenschappelijk actief voor haar 
promotie, maar ook daarbuiten. In december 2016 werd ze opleider Kindergeneeskunde 
in het cluster OOR-ON. Ze woont in Arnhem met haar man Menno Loos en hun kinderen 
Willemijn (2008), Sjoerd (2010) en Teun (2012).

